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ABSTRACT 
 
ALLYSON EVANS VAUGHN 
POSTMITOCHONDRIAL REGULATION OF APOPTOSIS IN 
NEURONS AND CANCER CELLS 
 (Under the direction of Mohanish Deshmukh, Ph.D.) 
 
 
The apoptotic pathway is a genetically conserved, energetic process that is essential 
for the development and homeostasis of organisms.  Aberrant apoptosis, however, can 
result in variety of diseases including neurodegeneration and cancer.  Apoptotic stimuli 
ultimately converge at the mitochondria, where cytochrome c is released into the cytosol 
to trigger formation of the apoptosome complex.  The active apoptosome then goes on to 
activate the caspase family of proteases which cleave a myriad of substrates, resulting in 
cell death.   
The core apoptotic components are ubiquitously expressed in cells, however some 
cell types (such as neurons and cancer cells) have an increased need to strictly regulate 
the apoptotic pathway.  Unlike normal mitotic cells, postmitotic neurons have little 
regenerative potential and must often last the lifetime of the organism.  Here, I identify 
novel ways in which neurons and cancer cells inhibit the apoptotic pathway at points 
downstream of cytochrome c.  Specifically, I describe mechanisms by which postmitotic 
neurons of the PNS and CNS posttranslationally inactivate cytochrome c and Apaf-1, 
respectively, in order to ensure their longterm survival.  In addition, my work suggests 
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that cancer cells may use mechanisms similar to those adapted by neurons in order to 
evade apoptosis.  
Despite a neuron’s ability to inhibit programmed cell death, these cells must still 
be able engage the apoptotic pathway during development or in the event of extreme 
stress.  Here, I uncover the mechanism by which cytochrome c becomes reactivated 
in sympathetic neurons during developmental apoptosis.  In addition, I examine how 
XIAP’s inhibition of caspases is overcome to allow neuronal apoptosis in response to 
DNA damage. 
Together, these results not only illustrate the importance of a strict regulation of 
apoptosis in differentiating neurons, but also identify the mechanisms by which these 
blocks are overcome to allow death.  I hope that a deeper knowledge of how the 
apoptotic pathway is reactivated in dying neurons could eventually lead to 
therapeutics to inhibit cell death in the context of neuronal pathologies, or to promote 
cell death in cancer. 
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I. CHAPTER ONE: 
Introduction to Apoptosis 
Although the first record of programmed cell death was likely made by Carl Vogt as 
early as 1842, observations in 1972 by Drs. J.F.R. Kerr, A.H. Wyllie, and A.C. Currie mark 
the birthdate of the term, apoptosis (Clarke and Clarke 1996).  As this team of scientists 
examined the tiny ovoid cytoplasmic fragments within sections of fixed tissue, they were 
surely unaware that within just forty years, their observations would lead to over 130,000 
journal articles and a Nobel Prize.   
Kerr and colleagues noticed that the phenotype of cells dying spontaneously within 
organisms were distinct from the swollen cells seen after injury.  While the latter cells would 
eventually burst, spilling their contents into surrounding tissue, this new form of death was 
characterized by cell shrinkage, chromatin condensation and the engulfment of these corpses 
by surrounding cells.  They deemed this new death process “apoptosis,” from the Latin 
meaning “dropping or falling off,” as of petals from flowers or leaves from trees (Kerr, 
Wyllie et al. 1972).  Apoptosis was quickly appreciated for its essential place in organismal 
development, from nematodes to mammals, and its role in countless human disease 
conditions ranging from cancer to neurodegeneration. 
   
A.  Apoptosis : a history of the key players 
While the implications for apoptosis as an important part of development and disease 
were easily recognized, more slowly to emerge from the scientific community has been an 
understanding of the genetic and biochemical processes that control it.  In the mid 1980s, 
studies from Dr. Bob Horvitz’s lab mapped the fate of every cell in the nematode C. elegans, 
leading to the identification of two genes, ced-3 and ced-4, required for programmed cell 
death.  Loss of function mutations in these genes allowed for the survival of the 131 cells 
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fated to die during the nematode’s development (Ellis and Horvitz 1986; Yuan and Horvitz 
1990).   Shortly after, the Horvitz lab identified the first antiapoptotic gene, ced-9, mutations 
of which cause excessive cell death in the nematode (Hengartner, Ellis et al. 1992).  These 
discoveries not only earned Dr. Horvitz the Nobel Prize, but paved the way for other 
researchers to look for conserved death machinery in the mammalian cell.    
The search for mammalian gene sequence homology to ced-3 uncovered an entire 
family of cysteine proteases, called caspases, which, following their activation, are 
responsible for cleavage of a myriad of cellular substrates within the cell (Yuan, Shaham et 
al. 1993; Hengartner and Horvitz 1994).  Of the many caspases, caspase-3 and caspase-9 are 
critical for developmental cell death, as mice deficient in both caspase-9 and caspase-3 are 
unable to undergo the extensive apoptosis that occurs during brain development (Kuida, 
Haydar et al. 1998).    
In an assay designed to identify proteins capable of cleaving and activating caspase-3, 
the mammalian homologue of ced-4 was discovered and named apoptotic protease-activating 
factor-1 (Apaf-1) (Liu, Kim et al. 1996; Zou, Henzel et al. 1997).  Although ced-4 and Apaf-
1 share sequence homology, mammalian Apaf-1 is more complex than its nematode 
precursor, with an additional regulatory element (a WD-40 repeat motif) at its C-terminus.  
This WD-40 domain renders Apaf-1 incapable of inducing activation of caspase-3 in the 
absence of an additional cytosolic partner (Hu, Ding et al. 1998).  This activator of Apaf-1, 
which was identified concomitantly with Apaf-1, turned out to be cytochrome c, a well 
studied and critical component of the mitochondrial respirator chain (Liu, Kim et al. 1996). 
With the discovery of ced-9 in the worm, it was realized that members of the 
mammalian Bcl-2 (B-cell lymphoma 2) family share significant sequence homology to this 
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antiapoptotic C elegans gene.  The importance of Bcl-2 as an inhibitor of apoptosis was soon 
appreciated because deletion of this protein or a family member, Bcl-xL, from mice results in 
massive apoptosis in the hematopoetic system and in the developing nervous system 
(Nakayama, Nakayama et al. 1993; Motoyama, Wang et al. 1995).  In addition, 
overexpression of Bcl-2 prevents mammalian cells from undergoing apoptosis.  Bcl-2-
mediated inhibition of apoptosis blocks caspase activation (Reed 1994), indicating that it 
functions upstream of the caspase cascade.  Bcl-2 is localized primarily to the 
outermembrane of the mitochondria (De Jong, Prins et al. 1992; Monaghan, Robertson et al. 
1992; Krajewski, Tanaka et al. 1993), and although this was curious at the time of its 
discovery, the implications of the mitochondrial protein, cytochrome c, in cell death 
suggested that Bcl-2 may play a role in the apoptotic regulation of cytochrome c (Chao and 
Korsmeyer 1998).    
 
1.  Bcl-2 and family members: gatekeepers of the mitochondria 
Bcl-2 was identified at an interchromosomal breakpoint in B-cell lymphoma, and was 
the first oncogene described to promote cancer survival not by enhancing proliferation, but 
by prohibiting cell death (Chao and Korsmeyer 1998).  Multiple proteins bearing sequence 
homology to Bcl-2 through Bcl-2 homology (BH) domains have since been identified, with 
members being divided into two groups: 1) The antiapoptotic Bcl-2 members include, but are 
not limited to, Bcl-2, Mcl-1 and Bcl-xL, which typically contain BH1 through BH4 domains 
and are often anchored to membranes through their hydrophobic carboxy-terminus (Martinou 
and Green 2001); and 2) the proapoptotic members of the Bcl-2 family (e.g., Bax, Bak, Bid, 
Bim, Puma, Noxa, et al.), which often only localize to mitochondrial membranes following a 
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death signal.  The proapoptotic members are further classified into: 1) “multidomain” 
members such as Bax and Bak which generally have sequence homology in BH1, BH2, and 
BH3 domains; and 2) “BH3-only” members including, but not limited to Bid, Bim, Bad, and 
Puma (Scorrano and Korsmeyer 2003).  These domains allow members of the Bcl-2 family 
to interact with each other, forming heterodimers or homodimers (Kelekar and Thompson 
1998).  It is thought that the BH3 domain of proapoptotic members of the Bcl-2 family can 
interact with a hydrophobic cleft formed by anti-apoptotic members, thus allowing the strict 
regulation of these protein (Harris and Thompson 2000). 
 
a.  Activation of the Bcl-2 family   
The activation of the apoptotic death pathway can occur in response to a wide variety of 
physiological as well as pathological cell death insults including growth factor deprivation, 
DNA damage, and ER stress (Vaux and Korsmeyer 1999).  In mammalian cells, cytosolic 
cytochrome c can trigger the activation of caspases and cellular death, thus the regulation of 
cytochrome c release by the Bcl-2 family is for many cells, the critical step in determining 
whether it will live or die.  Cell death insults engage BH3-only proteins such as Bid, Bim, 
and Puma which then localize to the mitochondria where they bind and displace anti-
apoptotic molecules like Bcl-2 and Mcl-1.  Through mechanisms that are not fully 
understood, the displacement of Bcl-2 members allows Bax and Bak to oligimerize at the 
mitochondria and initiate the release of cytohchrome c (Fig. 1.1), (Willis and Adams 2005).  
Although it is Bax and Bak which directly cause the release cytochrome c from the 
mitochondria, it is often the activation of upstream BH3-only members that are tightly 
regulated in response to apoptotic stimuli in a cell.  BH3-only members can be activated by a 
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variety of means both posttranscriptionally and transcriptionally.  For example, both Bim and 
Bad activity depend, in part, on their localization.  Upon growth factor stimulation, Bad is 
phosphorylated, allowing it to bind to the protein 14-3-3, which holds it harmlessly in the 
cytosol.  However, in the absence of growth factor stimulation, unphosphorylated Bad 
localizes to the mitochondria where it can interact with and inhibit the antiapoptotic protein, 
Bcl-xL (Zha, Harada et al. 1996; Puthalakath and Strasser 2002).  In addition, the activity of 
Bim is also inhibited by sequestration.  Whereas inactive Bim is tethered to the microtubule-
associated dynein motor complex, it can become unleashed and translocate to the 
mitochondria to inhibit Bcl-2 (Puthalakath, Huang et al. 1999).  The activity of the BH3 
protein, Bid, is regulated by cleavage.  In response to certain apoptotic stimuli that activate 
the extrinsic pathway of apoptosis, such as TNFα or Fas, full length Bid is cleaved to 
truncated Bid (tBid) which then can initiate cytochrome c release at the mitochondria 
(Esposti 2002).  BH3-only proteins are also often regulated via transcription (Freeman, Burch 
et al. 2004).  During embryogenesis,  the BH3 only protein  DP5/HRK is induced in neuronal 
tissues that undergo extensive apoptosis (Harris and Johnson 2001).  Bim is also 
transcriptionally induced in response to growth factor withdrawal in neuronal and 
hematopoetic cell types (Dijkers, Medema et al. 2000; Putcha, Moulder et al. 2001).  In 
addition, transcriptional upregulation of both Puma and Noxa by the tumor suppressor p53 
are important for DNA damage-induced apoptosis (Oda, Ohki et al. 2000; Nakano and 
Vousden 2001; Puthalakath and Strasser 2002). 
 
2.  Apoptosome formation and caspase activation 
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 While control of Bcl-2 family members and cytochrome c release often dictates the 
outcome of survival, caspases are the true executioners of programmed cell death.  Active 
caspases are responsible for the cleavage of a broad spectrum of cellular targets which results 
in the classical apoptotic morphology and the ultimate death of the cell.  In healthy cells, 
caspases are present as catalytically inactive zymogens, and can become activated in 
response to cytochrome c release from the mitochondria.  Caspase activation occurs in a 
cascade, with initiator caspases, such as caspase-9, -8, -2 and -10 cleaving and exposing the 
catalytic domain of effector caspases (caspase-3 and caspase-7), which go on to kill the cell 
(Shi 2002).  The activation of caspase-9 occurs by autoactivation, and requires the assembly 
of a large complex known as the apoptosome.  Apoptosome formation can be triggered in 
response to the release of cytochrome c from the mitochondria into the cytosol (Shi 2002; Shi 
2002).     
 The main function of the apoptosome is to initiate the enzymatic activity of caspase-
9.  The primary component of this 700-kD complex is the ced-4 homolog, Apaf-1 (Liu, Kim 
et al. 1996; Cain, Bratton et al. 2000).  Apaf-1 is comprised of an N-terminal CARD domain, 
a CED-4 Nucleotide Binding homology domain, and 13 WD-40 repeats at the C-terminus 
(Shi 2002), (Fig. 4.4).  In healthy cells, Apaf-1 is in an auto-inhibitory conformation whereby 
the WD-40 domain renders the N-terminal domains inaccessible.  However, in response to an 
apoptotic insult, cytosolic cytochrome c binds to the WD-40 domain, exposing Apaf-1’s 
caspase recruitment domain (CARD) and Nucleotide Binding Domain (NBD) (Hu, Benedict 
et al. 1998; Acehan, Jiang et al. 2002; Yu, Acehan et al. 2005).  In addition to the 
requirement of cytochrome c binding, the oligimerization of Apaf-1 into the apoptosome 
requires dATP binding to the NBD (Liu, Kim et al. 1996).  In response to cytochrome c 
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binding, dATP hydrolysis to dADP may occur followed by exchange to dATP (Kim, Du et 
al. 2005; Yu, Acehan et al. 2005).  This exchange seems to be important for defining a stable 
conformation of Apaf-1 to allow it to assemble with six other subunits into an active 
apoptosome.  This arrangement of oligomerized Apaf-1 exposes its CARD domains at the 
central hub of the wheel, which are responsible for caspase-9 recruitment and binding via 
CARD-CARD interactions.   
While effector caspases must be cleaved to become active, the activation of initiator 
caspase-9 does not require cleavage, but becomes activated after dimerization on the 
apoptosome (Boatright, Renatus et al. 2003; Boatright and Salvesen 2003).  In fact, the 
activity of processed caspase-9 is enhanced more than 1000-fold upon association with the 
apoptosome (Rodriguez and Lazebnik 1999).   However, this theory, known as the “induced 
proximity model,” may not explain caspase-9 activation entirely because constitutively 
dimeric caspase-9 remain considerably less active than those associated with Apaf-1 (Chao, 
Shiozaki et al. 2005).   In any case, the requirement for the apoptosome in activating caspase-
9 is clear as Apaf-1-/- animals exhibit phenotypes similar to caspase-9-/- animals, in that the 
absence of either inhibits cell death during development (Kuida, Zheng et al. 1996; Cecconi, 
Alvarez et al. 1998; Hakem, Hakem et al. 1998; Yoshida, Kong et al. 1998).   
 
B.  Regulators of apoptosome assembly and caspase activation 
Cytochrome c, Apaf-1, caspase-9, and dATP, are together sufficient for caspase 
activation and apoptosis to occur in vitro.  Yet, in most cell types, these dangerous 
components are maintained at high levels even in the absence of an apoptotic stimulus.  This 
suggests that other factors in an intact cell must regulate this core apoptotic machinery to 
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ensure that apoptosis occurs only at the right time and in the right place.  Over the last two 
decades, several such modifiers have been identified.  While controversy remains as to 
whether the release of cytochrome c is a point of no return for a cell, it is clear that neurons 
in which caspases are blocked downstream of cytochrome c release are able to recover the 
disruption of the mitochondria, and continue to function longterm (Neame, Rubin et al. 1998; 
Deshmukh, Kuida et al. 2000).  This finding indicates that the cell’s ability to regulate the 
apoptotic pathway downstream of cytochrome c release may be important in deciding 
whether a cell lives or dies.  Here, I will introduce several ways in which cytochrome c itself, 
the formation of the apoptosome, and the activity of caspases can be regulated.     
 
1.  Regulators of cytochrome c function 
 In healthy cells, cytochrome c functions to transfer electrons between integral 
mitochondrial membrane protein complexes in the respiratory chain of eukaryotes.  
However, in response to many apoptotic stimuli, cytochrome c relocates from the 
mitochondria into the cytosol where it is able to bind and activate the apoptosome, leading to 
caspase activation and death.  Cytochrome c is synthesized in the nucleus and is then 
imported into the mitochondria where a heme is attached.  Holocytochrome c (heme-
attached) is capable of activating the apoptosome, however, apocytcohrome c,which lacks the 
heme, has no proapoptotic activity, and when overexpressed can even act as a dominant 
negative (Yang, Liu et al. 1997; Martin and Fearnhead 2002).  While it is unclear whether 
apocytochrome c affects the proapoptotic activity of cytochrome c in living cells, it may 
prove a viable target to inhibit apoptosis in pathological situations (Martin and Fearnhead 
2002). 
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The expression level of cytochrome c may also determine a cell’s apoptotic potential.  
Several groups have shown that in response to an apoptotic stimulus, cytochrome c mRNA 
and protein are induced, enhancing its ability to induce apoptosis (Sanchez-Alcazar, Ault et 
al. 2000; Chandra, Liu et al. 2002).  Levels of cytcohrome c protein can also be regulated 
strictly at the translational level.  Overexpression of Smooth Muscle-20 (SM20), a prolyl 
hydroxylase that is induced upon growth factor mediated apoptosis in neurons, promotes a 
massive accumulation of cytochrome c protein with no apparent increase in cytochrome c 
mRNA (Straub, Lipscomb et al. 2003).  In addition, binding proteins can also affect the 
ability of cytochrome c to function.  One group has shown that Heat Shock Protein 27 
(HSP27) negatively regulates cytochrome c by binding to it and sequestering it away from 
Apaf-1 (Bruey, Ducasse et al. 2000).   
Posttranslational modifications of cytochrome c itself may also play a role in its ability 
to induce apoptosis.  For example, cytochrome c purified from yeast is unable to promote 
apoptosis, in part due to tri-methylation of Lysine 72.  Similarly, if mammalian cytochrome c 
is methylated on this residue, it loses its apoptotic activity (Kluck, Ellerby et al. 2000).  
Whether regulation of cytochrome c by methylation occurs in mammalian cells to control the 
apoptotic pathway is unknown.  The redox status of cytochrome c has also been implicated in 
its ability to promote cell death.  Some groups suggest that in vitro, oxidized cytochrome c is 
more apoptotically active than reduced cytochrome c (Pan, Voehringer et al. 1999; Hancock, 
Desikan et al. 2001; Suto, Sato et al. 2005).  This, however, is controversial, as other groups 
suggest there is no difference (Kluck, Martin et al. 1997; Hampton, Zhivotovsky et al. 1998).  
Chapter Two of this dissertation examines the role that cytochrome c redox plays in 
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apoptosis of intact cells.  In addition, Appendix B of this dissertation explores a novel way in 
which cytochrome c degradation may regulate its apoptotic activity. 
 
2.  Regulators of apoptosome activity 
In addition to regulation of cytochrome c itself, caspase activation and apoptosis can be 
controlled at the point of apoptosome assembly and activity.  Like cytochrome c, Apaf-1 and 
the activity other apoptosome components can be regulated by expression at the 
transcriptional level, as well as by various binding partners that either inhibit or enhance the 
activity of the apoptosome.   
 Our lab and others have recently shown that as dividing cells differentiate and 
become postmitotic, they lose their ability to undergo cytochrome c-mediated apoptosis.  
This increased resistance to apoptosis allows for survival of these postmitotic cells which 
must often last the lifetime of the organism.  In cardiomyocytes, myotubes, and neurons of 
both the CNS and PNS, this loss in sensitivity to cytochrome c is due, at least in part, to the 
dramatic decrease in Apaf-1 protein at the transcriptional level (Wright, Linhoff et al. 2004; 
Potts, Vaughn et al. 2005) (Chapter Four, and unpublished data).  In these cells, low levels of 
Apaf-1 render the apoptosome unable to activate sufficient caspases to overcome endogenous 
inhibitors of caspase activation (such as XIAP) found in the cell.  XIAP and its regulation are 
discussed in more detail below.  In addition, alternative splicing of Apaf-1 could regulate 
apoptosome function, as splice variants encoding fewer WD-40 repeats have reduced activity 
(Benedict, Hu et al. 2000). 
 The ability of Apaf-1 to assemble into the apoptosome and recruit caspase-9 can also 
be influenced by proteins and molecules which bind to and inhibit Apaf-1.  For example, 
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Heat shock protein-90 (HSP90 ) has been shown to bind Apaf-1 and inhibit apoptosome 
assembly, perhaps by restricting binding of cytochrome c to Apaf-1 (Pandey, Saleh et al. 
2000).  HSP70 may also regulate the apoptosome, but by binding to Apaf-1 and preventing 
caspase-9 processing (Beere, Wolf et al. 2000; Saleh, Srinivasula et al. 2000; Beere 2004).  
In addition, the proteins Aven and ProT can prevent apoptosome assembly (Chau, Cheng et 
al. 2000; Jiang, Kim et al. 2003), whereas TUCAN, APIP, JNK, and multiple truncated forms 
of caspase-9 can all prevent apoptosome activity by inhibiting caspase-9 recruitment and 
activation (Srinivasula, Ahmad et al. 1999; Angelastro, Moon et al. 2001; Pathan, Marusawa 
et al. 2001; Cao, Xiao et al. 2004; Tran, Andreka et al. 2007).   Apoptosome activity is also 
potentially negatively regulated by non-protein interactors such as nitric oxide donors, high 
levels of potassium, and intracellular nucleotides (Cain, Langlais et al. 2001; Zech, Kohl et 
al. 2003; Chandra, Bratton et al. 2006). 
 In contrast, some binding partners of Apaf-1 are able to increase apoptosome activity.  
NAC and hepatacellular carcinoma antigen 66 (HCA66) were shown to enhance caspase-9 
recruitment and activation through their association with Apaf-1 (Chu, Pio et al. 2001; 
Piddubnyak, Rigou et al. 2007).  Recently, putative HLA-DR-associated protein 1 (PHAP1) 
has been shown to increase activity of the apoptosome through unknown mechanisms, and its 
increased expression in breast cancer cells sensitizes them to cytochrome c-mediated 
apoptosis (Jiang, Kim et al. 2003; Schafer, Parrish et al. 2006). 
 Although to date no known sites of posttranslational  modifications have been 
identified on Apaf-1, Apaf-1 phosphorylation has been seen in correlation with regulation of 
caspase-9 processing on the apoptosome in response to PKA and Bcr-Abl (Deming, Schafer 
et al. 2004; Martin, Allan et al. 2005).  In Chapter Four of this dissertation, I provide 
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evidence suggesting that Apaf-1 phosphorylation can regulate apoptosis in the developing 
cerebellum.   
 
3.  XIAP and regulators of caspase activation 
The ability to regulate caspase activity is critical for a cell, because caspase activation 
can lead to a feed forward cascade that results in massive caspase processing, cleavage of a 
multitude of substrates and eventual cell death (Fischer, Janicke et al. 2003).  Caspase 
activity can be controlled by modification of caspases themselves, such as by 
phosphorylation or nitrosylation (Kim, Kwon et al. 2002; Allan, Morrice et al. 2003; Brady, 
Allan et al. 2005).  However, to date, the most potent and well characterized endogenous 
caspase regulators are members of the Inhibitor of Apoptosis Protein (IAP) family.   
The first IAP was discovered in a screen to identify regulators of host-cell viability 
during virus infection.  This screen uncovered the first IAP motif from baculovirus, now 
known as the baculovirus IAP repeat (BIR) domain, present in all IAP family members.  In 
mammalian cells, IAPs include XIAP, cIAP1, cIAP2, ML-IAP, NAIP, Survivin, and 
Apollon/Bruce (Salvesen and Duckett 2002).  While overexpression of many of the IAP 
family members are able to suppress apoptosis induced by a variety of stimuli (Duckett, 
Nava et al. 1996; Liston, Fong et al. 2003), XIAP is by far the most potent inhibitor of 
caspases (Salvesen and Duckett 2002; Scott, Denault et al. 2005; Eckelman and Salvesen 
2006; Eckelman, Salvesen et al. 2006).  Although the XIAP knockout mouse shows no overt 
phenotype (Harlin, Reffey et al. 2001), recently endogenous XIAP was identified as a critical 
regulator of caspase activation in cytochrome c-mediated apoptosis in neurons as well as 
cardiomyocytes.  While cytosolic cytochrome c alone is incapable of inducing apoptosis in 
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these postmitotic cells, XIAP deficient neurons and cardiomyocytes are susceptible to 
cytochrome c-mediated apoptosis (Potts, Singh et al. 2003; Potts, Vaughn et al. 2005).  This 
suggests that XIAP may act as a safety brake for caspase activation, only becoming 
important in situations of mitochondrial stress or accidental spillage of cytochrome c from 
the mitochondria.     
XIAP’s inhibition of caspases is direct.  XIAP contains three BIR domains, the third 
which can bind directly to cleaved and activated caspase-9, inhibiting its ability to interact 
with downstream substrate (Sun, Cai et al. 2000; Srinivasula, Hegde et al. 2001).  XIAP’s 
inhibition of caspase-3 and 7 is mediated by the small linker region of XIAP lying 
immediately N-terminal of the BIR2 domain, resulting in the reversible steric occlusion of 
caspase substrates (Chai, Shiozaki et al. 2001; Huang, Park et al. 2001; Riedl, Renatus et al. 
2001).  While the BIR domains at the N-terminus of XIAP have the ability to inhibit 
caspases, XIAP also contains a C-terminal RING finger domain which is known to have E3 
ubiquitin ligase activity  (Fig. C1), (Yang, Fang et al. 2000).  Although XIAP has been 
shown to ubiquitinate several target proteins in the apoptotic pathway (Silke, Ekert et al. 
2001; Suzuki, Nakabayashi et al. 2001; MacFarlane, Merrison et al. 2002; Sun 2003; 
Morizane, Honda et al. 2005), whether this domain plays a role in regulating apoptosis in 
intact cells is less understood.  Appendix C of this dissertation suggests that the RING 
domain of XIAP may play an antiapoptotic role in neurons. 
 
a.  Regulators of XIAP 
 Unlike for mammalian cells, the deletion of the XIAP homologue, DIAP1 in 
Drosophila leads to massive apoptosis and early lethality.  In Drosophila, DIAP1 activity is 
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inhibited by the DIAP1 binding proteins, Reaper, Grim, HID, and Sickle (Martin 2002).  
Immunoprecipitation experiments looking for similar regulators of XIAP in mammalian cells 
identified two XIAP binding proteins, SMAC/DIABLO, and Omi/HtrA2 which could 
enhance caspase activation in biochemical assays (Du, Fang et al. 2000; Verhagen, Ekert et 
al. 2000; Suzuki, Imai et al. 2001; Hegde, Srinivasula et al. 2002; Martin 2002; van Loo, van 
Gurp et al. 2002; Verhagen and Vaux 2002).  Unlike their Drosophila counterparts, both 
SMAC and HtrA2 are localized to the mitochondria in healthy cells where their 
mitochondrial targeting sequence is cleaved off, exposing an N-terminal AVPI (SMAC) or 
AVPS (HtrA2) sequence.   Upon apoptotic stimulation, SMAC and HtrA2 are released into 
the cytosol where they interact with XIAP.  SMAC inhibits XIAP through the binding of 
SMAC’s N-terminal AVPI motif with a groove made by the BIR2 and BIR3 domain of 
XIAP (Salvesen and Duckett 2002).  This interaction occurs at the same region as caspase-9-
XIAP binding, and at high enough ratios, can result in exclusion of caspase-9 from XIAP 
(Sun, Cai et al. 2000; Srinivasula, Hegde et al. 2001; Shi 2002).   SMAC binding to XIAP at 
the BIR2 domain also destabilizes and inhibits caspase 3/7 binding (Verhagen and Vaux 
2002).  
 Although SMAC is a powerful XIAP inhibitor in vitro, the endogenous role of SMAC 
is less understood.  We would anticipate that SMAC would be important as an XIAP 
inhibitor exclusively in cell types where XIAP is a critical inhibitor of caspase activation, 
such as neurons and cardiomyocytes (Du, Fang et al. 2000; Verhagen, Ekert et al. 2000; 
Ekert, Silke et al. 2001).  Indeed, ectopic expression of SMAC in these cell types inhibits 
XIAP, allowing cytochrome c to induce cell death (Potts, Singh et al. 2003; Potts, Vaughn et 
al. 2005).  Interestingly, however, data presented in Chapter Two of this dissertation suggest 
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that endogenous SMAC does not inhibit XIAP in neurons undergoing cytochrome c-
mediated apoptosis (Vaughn and Deshmukh 2007).  Despite the failure to identify a role of 
endogenous SMAC in apoptosis, understanding the mechanism by which SMAC inhibits 
XIAP may prove useful in cancer thereaputics, as expression of SMAC mimetics induces cell 
death in many cancer cells lines as well as mouse tumor models (Li, Thomas et al. 2004; 
Schimmer, Welsh et al. 2004; Bockbrader, Tan et al. 2005).  
 The activity of XIAP can also be regulated by mechanisms independent of SMAC or 
HtrA2.  In sympathetic neurons undergoing apoptosis in response to Nerve Growth Factor 
(NGF) deprivation, caspase activation proceeds due to the degradation of XIAP itself (Potts, 
Singh et al. 2003).  Although the mechanism by which this occurs remains elusive, the RING 
finger domain of XIAP has been shown to function as an E3 ligase, targeting itself for 
ubiquitylation (Yang, Fang et al. 2000).  As described earlier, the effectiveness of XIAP can 
be indirectly influenced by levels of Apaf-1, and hence, apoptosome activity.  When Apaf-1 
is low, caspase activation is minimal, making XIAP an affective inhibitor of cell death.  
However, high levels of Apaf-1 lead to massive caspase activation which overwhelms the 
ability of XIAP to inhibit apoptosis (Fig. 1.2) (Wright, Linhoff et al. 2004; Vaughn and 
Deshmukh 2007).  The regulation of XIAP activity via Apaf-1 levels is an crucial mechanism 
by which differentiating neurons and cardiomyocytes develop resistant to cytochrome c 
mediated apoptosis, and is also necessary for neuronal apoptosis in response to DNA damage 
(Wright, Linhoff et al. 2004; Potts, Vaughn et al. 2005; Vaughn and Deshmukh 2007),  This 
latter aspect of apoptotic regulation is examined in detail in Chapter Two.   
 
C.  ROS and Glucose Metabolism as Regulators of Apoptosis 
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 Reactive Oxygen Species (ROS) are generated as a result of normal cellular processes 
such as aerobic respiration, and can also be readily taken up by the cell from its environment.  
In a cell, ROS can cause damage to lipids, proteins, as well as DNA.  Gone unchecked, 
intracellular ROS accumulation causes oxidative insults that often result in cell death 
(Chandra, Samali et al. 2000).  ROS has been linked to apoptotic cell death in multiple 
scenarios including TNF, Fas, p53, myc, and virus-induced apoptosis (Polyak, Xia et al. 
1997; Chen, Willis et al. 2005).  In addition, well known endogenous inhibitors of apoptosis, 
such as Bcl-2, can act, in part, by modulating ROS in the cell (Mirkovic, Voehringer et al. 
1997).  Despite these links to apoptosis, whether ROS plays a direct mechanistic role in 
activating the apoptotic pathway is has not been extensively examined.   
Some research suggests, however, that ROS may directly influence cytochrome c 
release.  For example, ROS-mediated oxidation of cardiolipin on the mitochondrial 
membrane has been shown to facilitate its detachment from cytochrome c, and subsequent 
release of cytochrome c into the cytosol (Bayir, Fadeel et al. 2006; Orrenius, Gogvadze et al. 
2007).  This may play a role in disease conditions such as ischemia, where increases in ROS 
can result in cardiolipin oxidation and subsequent apoptosis (Polyak, Xia et al. 1997).  In 
addition, neuronal glutamate toxicity leads to cytochrome c release in a ROS dependent 
fashion (Orrenius, Gogvadze et al. 2007).  ROS signaling may also regulate physiological 
forms of cell death.  Neurons undergoing developmental apoptosis induced by NGF 
deprivation release cytochrome c in a ROS dependent manner (Dugan, Creedon et al. 1997; 
Kirkland and Franklin 2001).  In these neurons, ROS enhances the proapoptotic 
conformation of Bax, suggesting that ROS acts as a proapoptotic signal at multiple points in 
the apoptotic pathway.  In Chapter Two of this dissertation, I describe a novel mechanism by 
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which ROS regulates the apoptotic pathway via oxidation, and thus activation of cytochrome 
c itself.   
The disruption of cellular metabolism has long been associated with apoptotic cell 
death.  Many cell types require growth factors for their survival, and in the absence of these 
growth factors, cell metabolism becomes dysregulated, and apoptosis is induced.  Recently, 
enzymes as well as kinases required for glucose metabolism have been directly linked to 
regulation of the apoptotic pathway.  For example, the proapoptotic member of the Bcl-2 
family, Bad, has recently been identified in a complex containing glucokinase.  Not only can 
glucokinase influence the phosphorylation and apoptotic activity of Bad, but mice deficient 
in Bad exhibit defects in glucose homeostasis (Danial, Gramm et al. 2003)  Additionally, 
some growth factor regulated signaling kinases are intimately tied to both glucose 
metabolism and apoptosis.  In neurons, NGF promotes survival through the activation of 
AKT, whose activity is involved in glucose uptake and metabolism.  In response to NGF 
deprivation, glucose uptake and glycolysis are markedly reduced, and neurons undergo 
apoptosis (Deckwerth and Johnson 1993; Deckwerth and Johnson 1993).  Glucose 
metabolism through the pentose phosphate pathway may also be an important regulator of 
cellular apoptosis.  Inhibition of this pathway as a result of nutrient depletion has been shown 
to activate caspase-2 and subsequent death of Xenopus oocytes (Nutt, Margolis et al. 2005).  
Another mechanism by which glucose metabolism through the pentose phosphate pathway 
can regulate cell death and survival is by modulation of the oxidative state of the cell.  Flux 
through the pentose phosphate pathway supplies the cell with reducing equivalents of 
glutathione (GSH), one of the cell’s most abundant weapons against ROS (Chandra, Samali 
et al. 2000).  In situations of cellular stress such as DNA damage, cells attempt to control 
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ROS and apoptosis by increasing reduced glutathione (GSH) levels through the pentose 
phosphate pathway (Bensaad, Tsuruta et al. 2006).  In Chapter Three of this dissertation, I 
show that glucose metabolism through the pentose phosphate pathway inhibits ROS 
mediated activation of cytochrome c in neurons and cancer cells.  
 
D.  Apoptosis in the Animal: 
1.  Apoptosis in mammalian disease 
Not only is apoptosis critical for mammalian development and homeostasis, it also 
plays a role in the pathologies of many diseases including cancer, cardiomyopathy, 
autoimmune disease, inflammatory diseases and a wide variety of neuronal pathologies 
(Siegel, Chan et al. 2000; Fadeel and Orrenius 2005; Foo, Mani et al. 2005; Garg, Narula et 
al. 2005).  In this section I will discuss the role of apoptosis in cancer and neurodegneration 
in more detail.  
  
a. Apoptosis in cancer 
Cancer is a disease involving the expansion of dysregulated somatic cells and their 
invasion into normal tissues.  It is clear that cellular mutations that cause unchecked 
proliferation and invasion of cells are hallmarks of cancer, however, additional mutations that 
arise soon after to ensure that these cancer cells survive are critical for the progression of the 
disease (Evan and Vousden 2001).  Tumor cells that resist the response to activate apoptosis 
can arise through mutations that either inactivate pro-apoptotic genes, or activate prosurvival 
genes.  For example, deregulated expression of survival factors like insulin-like growth factor 
I and II (IGF-I, II) and activating mutations in the survival kinase, AKT, help confer 
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resistance of cancer cells to apoptosis (Datta, Brunet et al. 1999; Stambolic, Mak et al. 1999; 
Yu and Rohan 2000).  In addition, mutations that affect the core apoptotic machinery, 
including mutations that elevate the anti-apoptotic proteins Bcl-2 and Bcl-xL, can also aid in 
cancer cell survival (Seto, Jaeger et al. 1988; McDonnell, Deane et al. 1989).   
For most mitotic mammalian cells, inhibition of the apoptotic pathway downstream of 
cytochrome c release is unable to protect cells longterm, as release of cytochrome c from the 
mitochondria and subsequent loss of mitochondrial membrane potential results in a caspase-
independent commitment to death (McCarthy, Whyte et al. 1997; Brunet, Gunby et al. 1998; 
Ekert, Read et al. 2004).  Despite this, many cancer cells have acquired mutations affecting 
the apoptotic pathway at points downstream of cytochrome c.  For example, melanomas and 
leukemias tend to acquire mutations that cause loss of function or diminished expression in 
the proapoptotic gene, Apaf-1, or increased expression of IAPs (Vucic, Stennicke et al. 2000; 
Jia, Srinivasula et al. 2001; Soengas, Capodieci et al. 2001; Altieri 2004; Nachmias, Ashhab 
et al. 2004; Zangemeister-Wittke and Simon 2004; Wright and Duckett 2005).  The fact that 
these mutations downstream of cytochrome c release are advantageous to the survival of 
cancer cells, suggests that in some situations, cells can survive disruption of the mitochondria 
and cytochrome c release.  In fact, sympathetic neurons in which apoptosis is arrested after 
the point of cytochrome c release are able to recover upon removal of the apoptotic stimulus 
(Martinou, Desagher et al. 1999; Deshmukh, Kuida et al. 2000).  Recently, it was suggested 
that activity of the glycolytic enzyme GAPDH may play a role in the ability of cells to 
recover from mitochondrial membrane permeability, as GAPDH overexpressing cells are 
protected from caspase independent cell death following cytochrome c release (Colell, Ricci 
et al. 2007).  
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While all cancers must develop mutations that allow them to inhibit the apoptotic 
pathway, the mechanisms by which cancers do this are as diverse as the cancers themselves.  
A better understanding of how the apoptotic machinery is regulated across cancers lines 
could give us insight into specialized thereapeutics for these diseases.  For example, unlike 
the surrounding postmitotic neural tissue which is resistant to cytochrome c, many brain 
tumors such as glioblastoma and medulablastoma remain sensitive to cytosolic ytochrome c 
(Huang, YY et al., currently in revision for PNAS).  This differential sensitivity may allow us 
to induce apoptosis in cancer cells, while sparing the surrounding tissue.  In contrast, other 
cancers have developed mechanisms similar to those used by postmitotic neurons to evade 
apoptosis and ensure their longterm survival (Wright and Deshmukh 2006).  A novel 
mechanism by which both neurons and cancer cells inhibit the apoptotic pathway is the 
subject of Chapter Three of this dissertation. 
  
b.  Apoptosis in neuronal pathologies 
Unlike the rapid turnover of cells in proliferating tissues, postmitotic cells of the 
nervous system have limited regenerative potential and often survive the lifetime of the 
organism.  Thus, if excessive apoptosis occurs in these cells, the result can be devastating.  
Although apoptotic cells have been observed in tissues from patients with numerous 
neurodegenerative disorders and brain injuries, it is nevertheless difficult to demonstrate a 
role of apoptosis in these diseases.  First, apoptosis is a process which occurs rapidly, making 
quantitation of apoptotic cells in post-mortem tissues a difficult task.  Second, experiments to 
determine whether blocking apoptosis can prevent neuronal death cannot be easily done in 
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humans.  For such reasons, much of the evidence for apoptosis in neuronal disease comes 
from animal and cell-culture studies.   
 Although the immediate cell death occurring after focal ischemic stroke or traumatic 
injury is most likely a result of necrosis, cells in the surrounding penumbra of injury die more 
slowly and in an apoptotic manner.  In animal models of brain ischemia, cytochrome c is 
released from the mitochondria followed by activation caspases (Cheng, Deshmukh et al. 
1998; Fujimura, Morita-Fujimura et al. 1998).  In addition, patients with brain injury exhibit 
evidence of apoptosis such as caspase activation and increased Bax and p53 activation 
(Clark, Kochanek et al. 1999).  Interestingly, mice in which caspases are pharmacologically 
inhibited prior to stroke or traumatic brain injury show reduced cell death and improved 
symptoms (Hara, Fink et al. 1997; Yakovlev, Knoblach et al. 1997).      
 Alzheimer’s disease is correlated with death of neurons in the hippocampus, amygdala, 
and parts of the cortex.  Key characteristics of Alzheimer’s are accumulation of 
hyperphosphorylated tau protein and aggregates of amyloid-β peptide.  The importance for 
apoptosis in the pathology of Alzheimer’s is supported by the fact that cultured neurons 
exposed to amyloid-β undergo apoptosis, and exhibit an increased sensitivity to other stresses 
(Loo, Copani et al. 1993; Mattson 1998).   In addition, neurons deficient for the apoptotic 
proteins Bax, caspase-2, or caspase-12 show decreased sensitivity to amyloid-β (Nakagawa, 
Zhu et al. 2000; Selznick, Zheng et al. 2000; Troy, Rabacchi et al. 2000).    
 Huntington’s disease is an inherited neurodegenerative disorder resulting in 
degeneration of the striatum.  It is caused by an expansion of the CAG sequence in the gene 
Huntington, producing a protein with increased polyglutamine repeats (Brandt, Bylsma et al. 
1996).  In huntington patients, there is an increase in caspase activation and apoptosis of 
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lymphblasts (Sawa, Wiegand et al. 1999).  In addition, mouse models of Huntington show 
symptoms similar to those seen in humans, and have increased apoptosis in degenerating 
brain regions (Reddy, Williams et al. 1998).  In cultured cells, mutant Huntington is able to 
induce caspase-8 activation, and can itself be cleaved by active caspases, perhaps promoting 
neurotoxicity (Sanchez, Xu et al. 1999; Wellington and Hayden 2000).  Apoptosis has also 
been implicated in patients with amyotrophic lateral sclerosis (ALS).  Signs of apoptotic 
nuclei have been observed in these patients, and levels of the proapoptotic protein, Bax, are 
increased in ALS patients.  In mice, overexpression of Bcl-2 is able to inhibit the death and 
degeneration seen in mouse models of ALS (Kostic, Jackson-Lewis et al. 1997; Li, Ona et al. 
2000).   
 While it is clear that apoptosis occurs in many neuropathologies, it is possible that 
apoptosis is not a primary abnormality in the disease, but acts as a secondary affect of the 
disorder.  If this is the case, we must keep in mind that neuronal dysfunction could precede 
the apoptotic cell death seen in neurodegenerative disorders, making treatments that inhibit 
the apoptotic pathway unlikely to cure all symptoms. 
 
2.  Apoptosis in mammalian homeostasis and development 
Early work by Dr. Kerr and others observed apoptotic cells not only in the context of 
pathologies, but also in healthy adult tissues, suggesting a role for apoptosis in the normal 
regulation of cell populations.  In humans, as many as 100,000 cells are produced every 
second by mitosis, creating a need for an equal number to be removed by apoptosis to 
maintain organismal homeostasis (Vaux and Korsmeyer 1999).  The ability to undergo 
apoptosis quickly and efficiently may be more critical for certain cell types than others.  For 
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example, epithelial cells, which are constantly exposed to damaging agents such as 
ultraviolet light and reactive oxygen species (Truong-Tran, Grosser et al. 2003; Van 
Laethem, Claerhout et al. 2005) have a high turnover rate, and rapidly undergo apoptosis in 
order to eliminate the possibility of passing on debilitating mutations to future generations of 
cells (Green and Evan 2002).  In contrast, postmitotic neurons and cardiomycocytes have 
limited regenerative potential and therefore must strictly regulate the apoptotic pathway in 
order to last the lifetime of the organism (Wright and Deshmukh 2006).   
In addition to its role in maintaining homeostasis in the adult, apoptosis is a crucial part 
of development.  It has been implicated in processes from embryogenesis onwards, for the 
sculpting of tissues and organs, the removal of unwanted structures, and the elimination of 
damaged cells (Jacobson, Weil et al. 1997).   For example, the separation of digits requires 
programmed cell death, as inhibiting this process results in loss of digit formation (Milligan, 
Prevette et al. 1995; Jacobson, Weil et al. 1996).  Apoptosis is also required to remove 
unwanted cells such as those in the thymus which fail to rearrange their antigen receptors or 
recognize self-antigens (Marsden and Strasser 2003).   Importantly, extensive apoptosis 
occurs during development to ensure the proper set up of a functioning nervous system.  
 
a.  Apoptosis in neuronal development 
Mature mammalian neurons of the CNS and PNS are some of the longest lived cells in 
the body. However, during neuronal development, as many as 50% of neurons must undergo 
apoptosis in order to lay down a functional nervous system (Oppenheim 1991; Pettmann and 
Henderson 1998).  The most striking evidence for the importance of caspase-dependent 
apoptosis in mammalian neuronal development comes from genetic deletion studies of 
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caspase-3, caspase-9, and Apaf-1.  Although strain specific, these mice show massive defects 
in CNS development due to expansion of neuronal precursors and inhibition of immature 
neuronal death (Kuida, Zheng et al. 1996; Cecconi, Alvarez et al. 1998; Kuida, Haydar et al. 
1998).   In addition, mice deficient in the antiapoptotic protein, Bcl-xL show extensive 
apoptosis in immature postmitotic neurons of the central and peripheral nervous system 
(Motoyama, Wang et al. 1995).  These data indicate that while both mitotic neuronal 
precursors and postmitotic immature neurons undergo apoptosis in development, the exact 
mechanisms by which they do so may differ (Kuan, Roth et al. 2000; Roth, Kuan et al. 2000). 
Sympathetic neurons of the superior cervical ganglia have proved an excellent model to 
study apoptosis in response to both developmental and pathological apoptotic insults.  
Apoptosis of sympathetic neurons occurs during the developmental period when the neuron 
is innervating its target.  Competition for the trophic factor NGF, secreted by target cells, 
results in death of unsuccessful neurons, thus matching the number of target cells to 
innervating neurons (Deshmukh and Johnson 1997).  Much of what we know about the 
mechanisms controlling neuronal apoptosis have been discovered by studying sympathetic 
neurons deprived of NGF in vitro (Levi-Montalcini and Booker 1960; Gorin and Johnson 
1979; Crowley, Spencer et al. 1994; Smeyne, Klein et al. 1994; Putcha, Deshmukh et al. 
2000).  
The removal of NGF from cultured sympathetic neurons results in cell atrophy, 
condensation of the nuclei, fragmentation of neurites, and loss of structural integrity 
(Deshmukh and Johnson 1997).  Early signaling events that lead up to to these morphological 
changes have been well characterized.  NGF promotes survival by phosphorylating the TrkA 
receptor tyrosine kinase to activate the survival PI-3-kinase pathway, and in its absence, the 
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JNK/c-Jun pathway results in the increased expression and activation of the BH3 only 
protein, Bim (Putcha, Moulder et al. 2001; Whitfield, Neame et al. 2001; Putcha, Le et al. 
2003).  It is clear that protein translation, in part by inducing expression of Bim, is critical for 
apoptosis to proceed in these neurons, as cycloheximide (CHX) can potently block apoptosis 
after NGF deprivation (Martin, Ito et al. 1992).  At the mitochondria, Bcl-2 family proteins, 
including Bax initiate the release of cytochrome c from the mitochondria into the cytosol 
where the apoptosome forms.  Unlike apoptosis of mitotic cells, neuronal apoptosis requires 
two events.  The first, which triggers cytochrome c release, and a second, Bax-independent 
“competence pathway” to relieve XIAP’s inhibition on caspases.  NGF deprivation induces 
competence by targeting XIAP for degradation to allow cytochrome-c mediated cell death 
(Deshmukh, Du et al. 2002; Potts, Singh et al. 2003).  The events involved in neuronal death 
by NGF deprivation are summarized in Fig 1.3.   
 
b.  Increased regulation of apoptosis in neurons 
Despite the substantial apoptosis that occurs in neurons during development, these cells 
have developed multiple restrictions in the cell death pathway in order to meet the demand 
for their longterm survival.  These “checks” on the apoptotic pathway occur both upstream 
and downstream of cytochrome c release from the mitochondria, and have recently been 
reviewed (Wright and Deshmukh 2006).   
 
i. Elimination of Bax/Bak redundancy 
The proapoptotic members of the Bcl-2 family, Bax and Bak, can both induce the 
release of cytochrome c by acting directly on the mitochondria.  In most mitotic cells, these 
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proteins play redundant roles, with either one being sufficient to promote apoptosis in the 
event of an apoptotic signal (Wei, Zong et al. 2001).  However, in a variety of neuronal cell 
types, the deletion of Bax alone is sufficient to block cytochrome c release and inhibit 
apoptosis (Deckwerth, Elliott et al. 1996; Miller, Moulder et al. 1997; Johnson, Xiang et al. 
1998; White, Keller et al. 1998; Xiang, Kinoshita et al. 1998; Bar-Peled, Knudson et al. 
1999; Cregan, MacLaurin et al. 1999; Gibson, Han et al. 2001; Besirli, Deckwerth et al. 
2003; Sun, Gould et al. 2003; Wyttenbach and Tolkovsky 2006), while neurons derived from 
Bak deficient mice acquire no additional protection from apoptosis.  It was later discovered 
that neurons express a neuronal-specific splice variant of Bak (N-Bak) resulting in a 
premature truncation and elimination of the BH3 domains necessary for any direct 
proapoptotic activity (Sun, Yu et al. 2001; Uo, Kinoshita et al. 2005).  Thus, neurons have 
eliminated the redundancy of the proapoptotic activity of Bax/Bak, most likely to restrict 
apoptosis. 
 
ii.  Restriction of cell death by maintenance of mitochondrial membrane potential 
 In addition to the regulation of apoptosis upstream of cytochrome c release, neurons 
have adapted to strictly inhibit the apoptotic pathway even after the point of cytochrome c 
release.   In many cell types, the release of cytochrome c is accompanied by a rapid loss of 
mitochondrial membrane potential which represents a point of commitment to death even in 
the absence of caspase activation (McCarthy, Rubin et al. 1997; Brunet, Gunby et al. 1998; 
Ekert, Read et al. 2004).  In sympathetic neurons, however, the mitochondrial membrane 
potential is retained for some time after cytochrome c release, and in the presence of caspase 
inhibitors, neurons can recover from NGF deprivation induced cytochrome c release if NGF 
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is restored prior to loss of membrane potential (Martinou, Desagher et al. 1999; Deshmukh, 
Kuida et al. 2000). 
 
iii. Restriction of apoptosis by XIAP and Apaf-1 levels 
Although XIAP can readily inhibit caspase activation in vitro, the function of 
endogenous XIAP seems to be restricted to postmitotic cells such as neurons and 
cardiomyocytes (Potts, Singh et al. 2003; Potts, Vaughn et al. 2005).  Introduction of 
cytochrome c into the cytosol of intact mitotic cells or addition of cytochrome c to extracts of 
these cells results in caspase activation and apoptosis (Liu, Kim et al. 1996; Li, Srinivasan et 
al. 1997; Brustugun, Fladmark et al. 1998; Juin, Hueber et al. 1999; Wright, Linhoff et al. 
2004).  However, injection of cytochrome c into the cytosol of intact neurons or addition of 
cytochrome c to cerebellar extracts is only able to induce caspase activation and apoptosis if 
XIAP is first removed either by genetic deletion or by the addition of excess SMAC (Potts, 
Singh et al. 2003), (Chapter Four).   
Recently, our lab determined that the differential ability of XIAP to inhibit apoptosis in 
postmitotic cells as compared to mitotic cells is actually mediated by levels of Apaf-1, and 
thus, apoptosome function.  In mitotic cells, Apaf-1 expression and apoptosome activity are 
very high, and XIAP is unable to inhibit the massive resulting caspase activation.  However, 
in postmitotic neurons of the CNS, PNS, and in cardiomyocytes, levels of Apaf-1 are 
dramatically reduced, making endogenous XIAP an efficient inhibitor of caspase activation 
and cell death (Fig 1.2) (Wright, Linhoff et al. 2004; Potts, Vaughn et al. 2005; Vaughn and 
Deshmukh 2007),(Chapter Four).   The regulation of apoptosis at the point of apoptosome 
activity and caspase activity is not inherent, but develops as neuronal precursors differentiate 
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into postmitotic neurons.  While naïve PC12 cells, sympathetic neurons derived from E16 
mice, and mitotic cerebellar granule neuron precursors have high levels of Apaf-1 and are 
sensitive to cytochrome c, differentiated PC12 cells, sympathetic neurons derived from P1 
mice, and mature cerebellar neurons have low levels of Apaf-1 and develop an XIAP-
mediated resistance to cytochrome c (Wright, Linhoff et al. 2004), (Chapter Four).   
Once neurodevelopment is complete, neurons adopt an even more stringent control 
over the apoptotic pathway.  For example, sympathetic neurons gradually lose their 
dependence on NGF for survival (Angeletti, Levi-Montalcini et al. 1971; Goedert, Otten et 
al. 1978; Gorin and Johnson 1980; Ruit, Osborne et al. 1990; Easton, Deckwerth et al. 1997).  
Consistent with this, our lab has shown that in mature sympathetic neurons, Apaf-1 levels are 
even further decreased, resulting in a resistance to cytochrome c that is now XIAP 
independent (Wright, KM et al., currently in revision for JCB).  In neurons of the mature 
cortex and cerebellum, a similar XIAP-independent resistance to cytochrome c occurs, 
accompanied by a reduction in Apaf-1 as well as caspase-3 levels (Yakovlev, Ota et al. 
2001), (Chapter Four).  The molecular mechanisms underlying the resistance of cerebellar 
neurons to cytochrome c at different developmental stages will be examined in Chapter Four 
of this document. 
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Figure 1.1  Bcl-2 family regualation of cytochrome c release.  The BH3 only family of 
proteins typically act through binding and sequestering the anitapoptotic Bcl-2 proteins from 
Bax and Bak.  Bax and Bak act can directly at the mitochondria to induce the release of 
cytochrome c 
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Figure 1.2  Model showing how a marked reduction in Apaf-1 expression/activity in 
postmitotic cells engages XIAP as an affective inhibitor of caspases.   
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Figure 1.3 Model of NGF deprivation-induced apoptosis in sympathetic neurons.  NGF 
deprivation signals the activateion of JNK, which can activate proapoptotic members of the 
Bcl-2 family to induce cytochrome c release from the mitochondria into the cytosol.  
Cytosolic cytochrome c engages Apaf-1 and caspase-9 to form the apoptosome and initate 
cspase activation.  In addition to this signal to release cytochrome c, NGF deprivation also 
activates the “Development of Competnence” pathway which is necessary to overcome 
XIAP’s inhibition of caspases and allow apoptosis. 
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II.  CHAPTER TWO: 
Essential Postmitochondrial Function of p53 Uncovered in DNA Damage-Induced 
Apoptosis in Neurons 
A. Abstract 
In postmitotic sympathetic neurons, unlike most mitotic cells, death by apoptosis not 
only requires the release of cytochrome c from the mitochondria, but an additional step to 
relieve XIAP’s inhibition of caspases.  Here, we examine the mechanism by which XIAP is 
inactivated following DNA damage and find that it is achieved by a completely different 
mechanism than following apoptosis by NGF deprivation.  While NGF deprivation relieves 
XIAP by selectively degrading it, DNA damage overcomes XIAP via a p53-mediated 
induction of Apaf-1.  Unlike wildtype neurons, p53-deficient neurons fail to overcome XIAP 
and remain resistant to cytochrome c after DNA damage.  Restoring Apaf-1 induction in p53-
deficient neurons is sufficient to overcome XIAP and sensitize cells to cytochrome c.  While 
a role for p53 in apoptosis upstream of cytochrome c release has been well established, this 
study uncovers an additional, essential role for p53 in regulating caspase activation 
downstream of mitochondria following DNA damage in neurons. 
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B. Introduction 
Apoptosis is a highly regulated genetic process that is crucial for the development of 
the entire organism, including the nervous system.  Yet, apoptosis also plays an important 
role in neuronal injury and disease.  Aberrant apoptosis can result in too little cell loss as seen 
in cancer progression, as well as too much cell loss such as following stroke, spinal cord 
injury and in many neurodegenerative diseases (Yuan and Yankner 2000). 
 A crucial event of apoptosis is the activation of caspase proteases.  In mammalian 
cells, including neurons, caspase activation can be triggered by the release of cytochrome c 
from the mitochondria (Deshmukh and Johnson 1998; Wang 2001).  Once released, 
cytochrome c binds to Apaf-1, inducing its oligomerization and subsequent recruitment of 
the initiator caspase, procaspase-9, to form the apoptosome complex.  This complex results in 
activation of caspase-9, which then can cleave and activate downstream caspases such as 
caspase-3 which are responsible for cell death (Wang 2001).  
 These major components of the apoptotic pathway have been well characterized 
through the use of cell free biochemical studies and in intact cells using mitotic cell lines.  
However, recent evidence suggests that apoptosis is regulated very differently between 
mitotic and postmitotic cells.  For example, in many mitotic cells such as HeLa cells, HEK 
293 cells, primary fibroblasts, and naïve PC12 cells, the addition of cytochrome c to 
cytosolic extracts, or injection of cytochrome c into the cytosol of these cells induces rapid 
caspase activation and apoptosis (Liu, Kim et al. 1996; Li, Srinivasan et al. 1997; Brustugun, 
Fladmark et al. 1998; Juin, Hueber et al. 1999; Wright, Linhoff et al. 2004).   In contrast, 
cytochrome c, while necessary, is not sufficient to induce apoptosis in postmitotic cells such 
as sympathetic neurons, differentiated PC12 cells and cardiomyocytes (Deshmukh and 
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Johnson 1998; Vyas, Juin et al. 2004; Wright, Linhoff et al. 2004; Potts, Vaughn et al. 2005).   
Recently, the X-linked Inhibitor of Apoptosis Protein (XIAP) was identified as the critical 
regulator of caspase activation in these postmitotic cells (Potts, Singh et al. 2003; Potts, 
Vaughn et al. 2005).  XIAP is a member of a family of Inhibitor of Apoptosis Proteins (IAPs) 
that have been shown to regulate caspases by directly binding to and inhibiting their function 
(Salvesen and Duckett 2002).  Whereas cytosolic microinjection of cytochrome c is 
insufficient to induce apoptosis in wildtype neurons and cardiomyocytes, it is capable of 
doing so in XIAP-deficient neurons and cardiomyocytes (Potts, Singh et al. 2003; Potts, 
Vaughn et al. 2005). 
While sympathetic neurons are resistant to injection of cytochrome c into their cytosol, 
they are capable of undergoing cytochrome c-dependent apoptosis when induced by insults 
such as NGF deprivation and DNA damage (Deshmukh and Johnson 1997; Besirli, 
Deckwerth et al. 2003; Wyttenbach and Tolkovsky 2006).  Therefore, in order to undergo 
apoptosis, neurons must activate signaling events that cause cytochrome c release as well as 
inactivate XIAP.  The mechanism by which neurons overcome XIAP’s inhibition of caspases 
to become sensitive to cytochrome c has been termed ‘development of competence’ and has 
been examined in the model of NGF deprivation (Deshmukh and Johnson 1998).  In NGF 
deprivation-induced death, the ‘development of competence’ is dependent neither on Bax 
function nor protein synthesis, but occurs by the selective degradation of XIAP (Potts, Singh 
et al. 2003).  Whether other apoptotic stimuli, most importantly those involved in 
pathological situations that engage the cytochrome c-mediated apoptosome pathway, use the 
same or different mechanisms to overcome XIAP remains unknown.    
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Previous studies have shown that DNA damage can activate the intrinsic apoptotic 
pathway leading to cytochrome c release and caspase-dependent cell death in many cell types 
including sympathetic neurons (Besirli, Deckwerth et al. 2003; Morrison, Kinoshita et al. 
2003).   While DNA damaging agents are commonly used as chemotherapeutics in the 
treatment of many cancers, they can also cause widespread neurotoxicity in patients 
(Lazarus, Herzig et al. 1981).  DNA damage has also been observed in neurodegenerative 
diseases (Morrison, Kinoshita et al. 2003; Culmsee and Mattson 2005).  Therefore, 
understanding how apoptosis is regulated in neurons in response to DNA damage has clinical 
significance.   
The tumor suppressor p53 has been implicated in the regulation of apoptosis in 
response to DNA damage in mitotic cells as well as neurons (Miller, Pozniak et al. 2000; 
Schuler and Green 2001; Morrison, Kinoshita et al. 2003).  p53 has been shown to regulate 
cytochrome c release from the mitochondria both directly (Marchenko, Zaika et al. 2000; 
Chipuk, Kuwana et al. 2004), and through the transcriptional induction of proapoptotic Bcl-2 
proteins such as Bax, Puma, and Noxa (Schuler and Green 2001).  In this report, we find that 
p53 has an additional function to regulate apoptosis even after the point of mitochondrial 
cytochrome c release in neurons. 
We find that the mechanisms by which sympathetic neurons overcome XIAP’s 
inhibition of caspases are distinct between NGF deprivation and DNA damage.  Specifically, 
whereas NGF deprivation induces competence to relieve XIAP by targeting it for 
degradation, XIAP’s inhibition of caspases after DNA damage is overcome by a p53-
dependent increase in Apaf-1.  Thus, in the absence of p53, DNA damaged neurons are 
unable to execute apoptosis in response to cytochrome c because they are incapable of 
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relieving XIAP.  These results identify an essential postmitochondrial role of p53 in 
regulating apoptosis in mammalian neurons.     
 
C. Results 
1. Etoposide induces cytochrome c release and apoptosome-dependent death  
Sympathetic neurons undergoing apoptosis mediated by the apoptosome pathway 
require not only the release cytochrome c from mitochondria, but must also overcome 
XIAP’s strict inhibition of caspases.  While the mechanism by which XIAP is relieved has 
been previously studied in the model of NGF deprivation-induced neuronal death (Potts, 
Singh et al. 2003), here we examined how XIAP is overcome in sympathetic neurons 
undergoing apoptosis with DNA damage. 
First we established that sympathetic neurons treated with DNA damaging agents 
undergo a cytochrome c and apoptosome-mediated cell death. Sympathetic neurons were 
treated with the topoisomerase II inhibitor, etoposide, and cell death was assessed at various 
time points.  In response to etoposide, greater than 70% of sympathetic neurons undergo cell 
death by 48 hours.  This death was apoptotic as it could be blocked by the pan-caspase 
inhibitor, zVAD-fmk (Fig. 2.1A), and dying neurons exhibited Annexin V positive staining 
(Supplemental Fig. 2.1).  Furthermore, this etoposide induced death resulted in the release of 
cytochrome c (Fig. 2.1B) and engaged the apoptosome pathway.  Unlike wildtype neurons, 
sympathetic neurons isolated from Apaf-1 deficient mice were resistant to etoposide (Fig. 
2.1C).  Likewise, caspase-3 deficient sympathetic neurons have also recently shown to be 
resistant to etoposide-induced apoptosis (Wright, Vaughn et al. 2006).  
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In sympathetic neurons undergoing apoptosis via the cytochrome c-mediated 
apoptosome pathway, the removal of XIAP’s inhibition on caspases is necessary to permit 
death.   Whereas wildtype neurons are resistant, XIAP deficient neurons rapidly undergo 
apoptosis following injection of cytochrome c (Fig. 2.1D) (Potts, Singh et al. 2003).  The 
observation that etoposide engages death via the apoptosome pathway indicates that 
etoposide signaling must relieve XIAP’s inhibition of caspases in order for cells to die.  
Indeed, etoposide treatment for 24 hours (a time point at which cytochrome c release and cell 
death is minimal) is able to relieve inhibition of caspases as it sensitizes wildtype neurons to 
cytochrome c (Fig. 2.1D).  These results indicate that etoposide activates a mechanism that 
makes neurons permissive for cytochrome c-induced apoptosis before the neurons reach the 
point of cytochrome c release. 
 
2. Unlike NGF deprivation, etoposide-induced death requires translation to 
overcome XIAP 
 In the model of NGF deprivation-induced neuronal death, XIAP is inactivated by its 
selective degradation (Fig. 2.2A).  We were surprised to find, however, that neurons treated 
with etoposide underwent apoptosis yet maintained their XIAP levels (Fig. 2.2A, B).  These 
results indicate that the mechanisms by which NGF deprivation and DNA damage overcome 
XIAP are distinct.   
The development of competence can be directly determined by assessing the sensitivity 
of neurons to microinjection of cytochrome c.  Only after neurons develop competence 
(overcome XIAP activity) do they become sensitive to cytosolic cytochrome c.  While 
cytochrome c release is dependent on Bax and protein synthesis, in previous studies we have 
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shown that neither Bax nor protein synthesis is required for the development of competence 
via degradation of XIAP after NGF deprivation.  Therefore, NGF-deprived neurons, both 
Bax deficient and cycloheximide (CHX) treated, are unable to release cytochrome c, yet 
develop competence and die with microinjected cytochrome c (Fig. 2.2C), (Deshmukh and 
Johnson 1998). 
As the ‘development of competence’ pathway in etoposide-treated neurons appeared 
distinct and did not involve the degradation of XIAP, we asked whether this pathway was 
dependent on Bax or protein synthesis.  Bax-deficient or wildtype cycloheximide-treated 
sympathetic neurons were exposed to etoposide for 24 hours, followed by microinjection of 
cytochrome c and assessment of cell survival.  Like the NGF-deprived condition, etoposide 
treatment induced competence in the Bax-deficient neurons (Fig. 2.2D).  However, unlike 
NGF-deprived neurons, etoposide-treated neurons failed to develop competence in the 
presence of cycloheximide and remained resistant to cytochrome c (Fig. 2.2D).  These results 
indicate that the mechanism by which XIAP is overcome to develop competence in 
etoposide-treated neurons requires protein synthesis.    
 
3. Apaf-1 is markedly induced in etoposide-treated sympathetic neurons 
We have shown previously that Apaf-1 levels and the ability of XIAP to inhibit 
apoptosis are inversely coupled in cells (Wright, Linhoff et al. 2004).  Under conditions 
where Apaf-1 levels are low, such as in postmitotic sympathetic neurons and 
cardiomyocytes, endogenous XIAP is an effective inhibitor of caspases (Potts, Singh et al. 
2003; Potts, Vaughn et al. 2005).  In contrast, in mitotic cells where Apaf-1 levels are high, 
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equivalent levels of XIAP are unable to strictly block caspase activation in response to 
cytosolic cytochrome c (Wright, Linhoff et al. 2004; Potts, Vaughn et al. 2005). 
Based on this observation, we speculated that an increase in Apaf-1 levels could be a 
mechanism by which sympathetic neurons disengage XIAP’s brake on caspase activation in 
response to DNA damage.  We examined whether Apaf-1 levels are increased in sympathetic 
neurons treated with etoposide.  Indeed, Western analysis shows that Apaf-1 protein levels 
were elevated by 24 hours following treatment with etoposide (Fig. 2.3A).  In contrast, no 
significant increase in Apaf-1 was seen after NGF deprivation.  This increase in Apaf-1 with 
DNA damage was also seen at the transcriptional level (Fig. 2.3B).  Similar increases in 
Apaf-1 have also been reported in cortical neurons following treatment with camptothecin or 
after traumatic brain injury (Fortin, Cregan et al. 2001; Yakovlev, Ota et al. 2001).  These 
data suggest that Apaf-1 induction could be necessary for disengaging XIAP’s brake on 
caspase activation to permit apoptosis in neurons. 
 
4. p53 deficient neurons are unable to develop competence in response to DNA 
damage 
    In the context of cell death, two functions of p53 have received much attention.  
First, p53 transcriptionally regulates proapoptotic Bcl-2 family members such as Bax, Puma 
and Noxa in response to DNA damage, which are important upstream activators of 
cytochrome c release (Miyashita and Reed 1995; Oda, Ohki et al. 2000; Yu, Wang et al. 
2003).  Second, a transcriptional-independent role has been described for p53 in which it acts 
directly at the mitochondria to induce cytochrome c release (Marchenko, Zaika et al. 2000; 
Mihara, Erster et al. 2003; Chipuk, Kuwana et al. 2004; Chipuk, Bouchier-Hayes et al. 2005).  
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Recently, p53 has also been identified as a transcriptional activator of Apaf-1, but the 
importance of this activity has remained unclear (Fortin, Cregan et al. 2001; Moroni, 
Hickman et al. 2001). 
Since the increase in Apaf-1 could be a potential mechanism by which XIAP is relieved 
to permit neuronal apoptosis, we investigated the specific importance of p53 in this process.   
First, we examined whether p53 deficiency blocks apoptosis in sympathetic neurons in 
response to etoposide.  While less than 10% of wildtype sympathetic neurons remained 
viable 60 hours after etoposide treatment, greater than 80% of p53 deficient neurons survived 
at this time (Fig. 2.4A).  Since p53 has been shown to induce Puma, an event which is 
required for cytochrome c release in response to DNA damage in sympathetic neurons 
(Wyttenbach and Tolkovsky 2006), we anticipated that p53 deficient neurons might be 
resistant to apoptosis at multiple points in the apoptotic pathway.   Consistent with this 
known pre-mitochondrial function of p53 in neurons, while the majority of wildtype neurons 
had released cytochrome c by 36 hours of etoposide treatment, p53 deficient neurons retained 
cytochrome c in the mitochondria (Supplemental Fig. 2.2).   
To specifically examine whether p53 is also important downstream of cytochrome c, 
we investigated whether p53 deficient neurons fail to become sensitive to cytochrome c 
following DNA damage.  Wildtype and p53 deficient neurons were treated with etoposide for 
24 hours (a timepoint at which the majority of neurons have not released cytochrome c; 
Supplemental Fig. 2.2), followed by microinjection with cytochrome c.  Activating the 
apoptotic pathway directly at the point of cytosolic cytochrome c is necessary as it allows 
one to bypass the known defect of cytochrome c release found in p53 deficient neurons 
(Supplemental Fig. 2.2).  Unlike etoposide-treated wildtype neurons which underwent 
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apoptosis after cytochrome c injections, etoposide-treated, p53 deficient neurons remained 
resistant to cytochrome c injection unless XIAP was removed by co-injection of SMAC 
protein (Fig. 2.4B).  Injections with rhodamine dextran alone did not induce death in 
wildtype or p53 deficient etoposide-treated neurons. 
To determine whether the inability of p53 deficient neurons to develop competence was 
specific to DNA damage, we asked whether p53 deficient neurons were able to develop 
competence in response to NGF deprivation.  Wildtype or p53 deficient sympathetic neurons 
were deprived of NGF in the presence of cycloheximide (CHX) (to prevent cytochrome c 
release) for 24 hours.  Consistent with our expectations, both wildtype and p53-deficient 
neurons developed competence and were sensitive to microinjection of cytochrome c (Fig. 
2.4C).  Thus, p53 is selectively important for the development of competence in response to 
DNA damage, which involves upregulation of Apaf-1, but not NGF deprivation, which 
involves the degradation of XIAP. 
To confirm that the inability of p53-deficient neurons to undergo apoptosis in response 
to cytochrome c was due to XIAP’s inhibition of caspases, we asked whether p53-deficient 
neurons became sensitive to cytochrome c following direct inactivation of XIAP.  Indeed, 
injection of cytochrome c along with SMAC (an inhibitor of IAPs), but not cytochrome c 
alone nor SMAC alone, induced apoptosis in p53-deficient neurons, indicating that all the 
necessary apoptosomal components are present and capable of activation in the p53-deficient 
neurons if XIAP is removed (Supplemental Fig. 2.3). 
Thus, in sympathetic neurons, p53 is required to overcome XIAP (develop competence) 
to permit cytochrome c-mediated apoptosis following DNA damage. 
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5. p53 links Apaf-1 induction with XIAP inactivation during DNA damage-
induced apoptosis in neurons 
 To investigate whether p53 is necessary for the induction of Apaf-1 protein in 
response to DNA damage, neurons from p53 heterozygous or p53-deficient mice were either 
left untreated or treated with etoposide.  Western analysis revealed that while levels of Apaf-
1 protein increased following etoposide treatment in wildtype and p53-heterozygous neurons 
(Fig. 2.3A; 2.5A), Apaf-1 was not induced in p53-deficient neurons under these conditions 
(Fig. 2.5A).  Thus, etoposide-mediated induction in Apaf-1 in sympathetic neurons was p53-
dependent.  We also note that p53 deficiency did not affect basal levels of Apaf-1, as Apaf-1 
levels were comparable between p53-heterozygous and p53-deficient neurons. 
If the resistance of p53-deficient neurons to develop competence is due to the specific 
inability of these cells to upregulate Apaf-1 in response to etoposide, then restoration of 
Apaf-1 induction in p53-deficient neurons would be expected to restore the ability of these 
neurons to develop competence following DNA damage.  To test this, p53-deficient 
sympathetic neurons were injected with plasmid DNA encoding either Apaf-1 or vector 
alone, along with EGFP to mark injected cells.  After 24 hrs, neurons were treated with 
etoposide for 24 hours, followed by microinjection of cytochrome c.  Injection of cytochrome 
c into Apaf-1-expressing p53-deficient neurons resulted in complete apoptosis by 6 hours.  
However, injection of rhodamine alone into Apaf-1 expressing cells, or cytochrome c into 
cells expressing empty vector did not induce death (Fig. 2.5B).  These data show that by 
restoring the induction of Apaf-1 by overexpression, DNA damaged, p53-deficient 
sympathetic neurons regained the ability to develop competence and overcome XIAP’s 
inhibition of caspases.   
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Together, these data show that a p53-mediated induction of Apaf-1 is necessary to 
overcome XIAP and permitting cytochrome c to induce apoptosis in neurons in response to 
DNA damage. 
 
D. Discussion 
In this study, we have examined how the strict inhibition of caspases by endogenous 
XIAP is relieved when neurons undergo apoptosis following DNA damage.  We find that the 
mechanisms by which XIAP is overcome in sympathetic neurons undergoing developmental 
apoptosis by NGF withdrawal and pathological apoptosis by DNA damage are distinct.  
Whereas NGF deprivation relieves XIAP by its selective degradation (Potts, Singh et al. 
2003), XIAP levels remained unchanged after DNA damage (Fig. 2.2A,B).  In contrast to 
NGF deprivation, the development of competence after DNA damage required protein 
synthesis.  Consistent with this requirement, we found that Apaf-1 was markedly induced in 
neurons undergoing apoptosis with DNA damage (Fig. 2.3A).  Our results identify an 
important function of p53 in the development of competence, as p53-deficient neurons failed 
to induce Apaf-1 after DNA damage (Fig. 2.5A).  We examined the specific importance of 
Apaf-1 upregulation in relieving XIAP during DNA damage-induced apoptosis, and found 
that in the absence of an Apaf-1 induction, p53-deficient neurons failed to develop 
competence in response to DNA damage (Fig. 2.4B).  Importantly, restoring Apaf-1 
induction by overexpression of Apaf-1 in p53-deficient neurons restored their ability to 
relieve XIAP, permitting cytochrome c to induce apoptosis (Fig. 2.5B).   
These results validate our previous model which proposed that the effectiveness of 
endogenous XIAP to inhibit apoptosis is coupled to Apaf-1 activity in cells.  Mitotic cells, 
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which express high levels of Apaf-1, readily undergo apoptosis in response to cytochrome c , 
without the need to eliminate endogenous XIAP.  In contrast, sympathetic neurons have low 
levels of Apaf-1, allowing endogenous XIAP to effectively inhibit cytochrome c-dependent 
caspase activation (Wright, Linhoff et al. 2004).  As Apaf-1 is the limiting component of the 
apoptosome in these neurons, this model predicts that elevating levels of Apaf-1 alone would 
be sufficient to increase the number of functional apoptosomes and overcome XIAP.  In this 
study we describe a pathological situation in which the coupling of Apaf-1 and XIAP 
becomes a critical regulator of caspase activation.  In response to DNA damage, sympathetic 
neurons overcome XIAP and develop sensitivity to cytochrome c by specifically 
upregulating Apaf-1.  Induction of Apaf-1 was the only step required by etoposide to 
sensitize p53-deficient neurons to cytochrome c.  p53-deficient cells in which Apaf-1 
induction had been restored by overexpression underwent apoptosis in response to 
cytochrome c even in the absence of etoposide treatment (Supplemental Fig. 2.4). 
Strict control of caspase activation by XIAP in neurons presumably functions as a 
safety brake that would prevent apoptosis from occurring in the event of accidental 
mitochondrial damage resulting in cytochrome c release.  However, in situations where death 
is inevitable, such as during development or after irreparable DNA damage, the efficient 
removal of this brake is important as it would permit apoptosis thereby avoiding the negative 
side effects of necrosis.  Indeed, both NGF deprivation and DNA damage activate specific 
pathways that efficiently relieve XIAP at a time that precedes the release of cytochrome c 
from mitochondria (Fig. 2.1D, 2.4B), (Potts, Singh et al. 2003).  Thus, apoptosis in XIAP-
deficient neurons, while no longer needing the pathway to relieve XIAP, is still dependent on 
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the release of cytochrome c and therefore occurs with a time course that is indistinguishable 
from wildtype neurons (Supplemental Fig. 2.5), (Potts, Singh et al. 2003). 
Although the major components of the intrinsic pathway of apoptosis are conserved in 
both developmental (NGF deprivation) and pathological (DNA damage) apoptosis in 
sympathetic neurons, this study has identified unique differences in the way this pathway is 
regulated between these two models.  While removal of NGF in these neurons selectively 
targets XIAP for degradation, DNA damage overcomes XIAP by a p53-mediated induction 
of Apaf-1 (model in Fig. 2.6A).  We note that biochemical and overexpression studies have 
shown that mature SMAC can also directly bind XIAP and inhibit its activity (Verhagen and 
Vaux 2002).  However, endogenous SMAC does not function to relieve XIAP following 
DNA damage in neurons, as both wildtype and SMAC-deficient sympathetic neurons 
undergo apoptosis with a similar timecourse following etoposide treatment (Fig. 2.6B).  
Thus, neurons appear to have evolved multiple SMAC-independent pathways that are 
sufficient to relieve XIAP and permit cytochrome c-dependent apoptosis.  Similar pathways 
may also be engaged in other postmitotic cells such as cardiomyocytes where relieving XIAP 
is necessary for apoptosis.   
Apaf-1 has been shown to be induced in a p53-dependent manner in response to 
camptothecin in cortical neurons (Fortin, Cregan et al. 2001).  However, whether the p53-
mediated induction of Apaf-1 was necessary for neuronal apoptosis was not specifically 
examined.  Indeed, p53 deficiency blocks apoptosis in response to DNA damage in many 
cells including neurons (Morrison, Kinoshita et al. 2003; Michalak, Villunger et al. 2005).  
However, studies investigating the mechanism of p53 action have primarily focused on 
events preceding cytochrome c release.  For example, proapoptotic members of the Bcl-2 
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family proteins such as Bax, Noxa, and Puma are transcriptional targets of p53, and their 
upregulation can promote cytochrome c release in cells (Schuler and Green 2001; 
Wyttenbach and Tolkovsky 2006).  In addition, recent studies show that p53 can directly 
induce cytochrome c release by localizing to mitochondria (Marchenko, Zaika et al. 2000; 
Mihara, Erster et al. 2003; Chipuk, Kuwana et al. 2004; Chipuk, Bouchier-Hayes et al. 2005).  
Our results now uncover an essential postmitochondrial function of p53 in apoptosis.  While 
p53-mediated induction of Apaf-1 is likely to occur in multiple cell types exposed to DNA 
damage, we expect that it is only required in cells where the inactivation of XIAP is 
necessary for cytochrome c-mediated apoptosis, such as in neurons and cardiomyocytes.  In 
addition, as overexpression of XIAP is seen in many cancers (Liston, Fong et al. 2003), our 
results predict that p53 activity could also overcome XIAP’s inhibition of caspases by 
elevating Apaf-1 in such cancers. 
Several studies show that p53 is induced following a variety of neuronal injury 
paradigms such ischemia, hypoxia, and excitotoxicity (Morrison, Kinoshita et al. 2003; 
Culmsee and Mattson 2005) as well as in neurodegenerative diseases such as Amyotrophic 
Lateral Sclerosis (Martin 2000).  Importantly, mice deficient in p53 are protected against 
glutamate or kainic acid-excitotoxic injury (Morrison, Wenzel et al. 1996) and ischemic brain 
damage (Crumrine, Thomas et al. 1994).  Our results predict that in these models, p53 
deficiency would inhibit neuronal apoptosis not only by blocking cytochrome c release, but 
also by preventing the ability of these neurons to overcome XIAP, thus regulating apoptosis 
at both pre- and post-mitochondrial steps. 
Having multiple checkpoints in the regulation of apoptosis, and being able to precisely 
regulate these checkpoints, is critical for balancing a neuron’s long-term survival with the 
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need to undergo apoptosis when physiologically appropriate.  An understanding of how these 
checkpoints are differentially regulated between mitotic and postmitotic cells is clinically 
significant as it allows for the development of therapeutics that could inhibit or activate 
apoptosis in selective cells in the context of neurodegenerative diseases or cancers. 
 
E. Materials and Methods 
Reagents 
 All reagents were purchased from Sigma (St. Louis, MO) or Fisher Scientific 
(Pittsburgh, PA) unless otherwise stated.  Collagenase and trypsin were purchased from 
Worthington Biochemical Corporation (Freehold, NJ), and cycloheximide was purchased 
from Tocris Cookson (Ellisville, MO).  The pan-caspase inhibitor, zVAD-fmk, was 
purchased from Enzyme Systems Products.  The Apaf-1 cDNA was a gift from Dr. Gabriel 
Nunez (University of Michigan, Ann Arbor).  Recombinant SMAC protein was purified from 
bacteria as described previously (Potts, Singh et al. 2003). 
 
Sympathetic Neuronal Cultures 
    Primary sympathetic neurons were dissected from the superior cervical ganglia of 
postnatal day zero to one mice (P0-P1), and maintained in culture as described previously 
(Deshmukh, Vasilakos et al. 1996).  Cells were plated on collagen-coated dishes at a density 
of 60,000 cells per well for Western or RT-PCR analysis, or 10,000 cells per well for 
microinjection, survival counts, or immunofluorescence experiments.  Sympathetic neurons 
were grown for 4-5 days in NGF contained media before treating them with experimental 
conditions.  For treatments, etoposide was used at a concentration of 20 µM.  For NGF 
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deprivation, cultures were rinsed three times with medium lacking NGF, followed by the 
addition of goat anti-NGF neutralizing antibody to this media.  Other conditions required the 
addition of 1 ug/ml cycloheximide or 50 µM zVAD-fmk. 
ICR outbreed mice (Harlan Sprague Dawley) were used for all experiments except 
those involving Bax-deficient, Apaf-1-deficient and p53-deficient sympathetic neurons.  The 
genetic background of Bax-deficient, Apaf-1-deficient, p53-deficient, and SMAC-deficient 
mice is C57BL/6; wildtype littermates were used as controls in these experiments.  Apaf-1-
deficient mice were generated by Dr.Joachim Herz (UT Southwestern) (Honarpour, Du et al. 
2000) and were kindly provided by the laboratory of Dr. Susan Ackerman (Jackson 
Laboratories).  Heterozygous p53 mice were obtained from Jackson Laboratories (Maine).  
SMAC-deficient mice were provided by the laboratory of Dr. Tak Mak (University of 
Toronto).  Our methods for breeding and genotyping Bax-deficient mice are described 
previously (Deckwerth, Elliott et al. 1996).  The specific primers used to genotype Apaf-1, 
p53, or SMAC deficient mice are listed in the online supplemental materials and methods 
section. 
 
Immunofluorescence analysis 
      The status of cytochrome c (whether intact in the mitochondria or released) was 
examined by immunofluorescence.  Briefly, sympathetic neurons were cultured for 4 days 
following which they were left untreated or treated with 20 uM of etoposide for various time 
points.  Neurons were then fixed in 4% paraformaldehyde and incubated overnight in anti-
cytochrome c primary antibody (556432, BD Biosciences) followed by a 2 hour incubation 
 53
with anti-mouse Cy3 secondary antibody (Jackson Labs).  Nuclei were stained with Hoechst 
33258 (Molecular Probes). 
 
Microinjection and quantitation of cell survival 
 Our method or microinjecting sympathetic neurons with cytochrome c has been 
described previously (Wright, Linhoff et al. 2004).  Immediately after injections, the number 
of viable cells injected was determined by counting rhodamine-positive cells that had intact 
phase-bright bodies.  This method of assessing neuronal survival correlates well with other 
cell survival assays such as trypan blue exclusion and staining with calcein AM (Potts, Singh 
et al. 2003)  At various times after injections, the number of viable injected neurons 
remaining was determined by using the same counting criteria and expressed as a percentage 
of the original number of microinjected cells.   
    In experiments involving microinjection of DNAs, the Apaf-1 expressing plasmid or 
empty vector was injected into neurons.  The nucleus was injected with 200 ng/ul of the 
plasmid DNA along with 50 ng/ul of EGFP-expressing DNA (Clonetech laboratories, Inc.) in 
microinjection buffer.  After 24 hours to allow for expression, GFP-expressing cells were 
identified by fluorescence microscopy and re-injected with cytochrome c.  The survival of 
these double injected cells was assessed by morphological criteria.   
 
Western Blot analysis 
    Western analysis was performed as described previously (Potts, Singh et al. 2003).  
The following antibodies were used; anti-Apaf-1 (13F11; Alexis Biochemicals), anti-XIAP 
(AF822; R&D Systems), anti-LDH (Rockland), anti-alpha-Tubulin (Sigma).  Anti–
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mouse/rabbit HRP-conjugated secondary antibodies were purchased from Pierce Chemical 
Co.  For quantitation, Western blots were developed with ECL-plus reagents (Amersham 
Biosciences) and analyzed on a Typhoon fluorescent imager (Amersham Biosciences) using 
Image Quant software (Amersham Biosciences).   
 
Quantitation of mRNA expression 
    Our method of quantitative RT-PCR analysis has been described previously (Potts, 
Singh et al. 2003). The gel was stained with Sybr Green I (Molecular Probes) and visualized 
on a Typhoon fluorescence imager (Amersham Biosciences) and quantitated using 
ImageQuant software. 
 
Annexin V and PI staining 
     Sympathetic neuronal cultures were treated with etoposide for 36 hours, followed by 
staining for Annexin V and Propidium Iodide (PI) using the TACS Annexin V-FITC 
Apoptosis Detection kit (R&D Systems) according to the manufacturer’s protocol.  Briefly, 
cells were washed in PBS followed by a 15 min incubation with 2.5 ug/mL PI, and 1.25 
ug/mL AnnexinV-FITC.  Cells were washed twice and viewed immediately on a Leica 
inverted fluorescence microscope.   
 
Image Acquisition and Processing 
All images were acquired by a Hamamatsu ORCA-ER digital B/W CCD camera 
mounted on a Leica inverted fluorescence microscope (DMIRE 2).  The image acquisition 
 55
software was Metamorph version 5.0 (Universal Imaging Corporation).  Images were scaled 
down and cropped in Adobe Photoshop to prepare the final figures. 
 
Primers 
Primers used to genotype the following knockout mice: 
Apaf-1:  Forward WT: 5´ GCCTGCCATCCCATAGATGGT 3´ 
   Forward KO: 5´ GATTGGGAAGACAATAGCAGG 3´ 
   Reverse (common): 5´ CAGCAAGGCCTTTACCTGTTG 3´ 
  WT: 900 base pairs; Apaf-1 KO: 600 base pairs 
 
p53:  Forward WT: 5′ ATAGGTCGGCGGTTCAT 3′   
Reverse WT: 5′ CCCGAGTATCTGGAAGACAG 3′  
Forward KO: 5′ TCCTCGTGCTTTACGGTATC 3′ 
Reverse KO: 5′ TATACTCAGAGCCGACCT 3′ 
WT: 600 base pairs; p53 KO: 280 base pairs 
 
SMAC:             Forward WT: 5’ GAGACAGAAAGGTAGAGGTGC 3’ 
Forward KO: 5’ GGTGGATGTGGAATGTGTG 3’ 
Reverse (common): 5’ TATAGAGCCCGAATGTCAGAA 3’ 
WT: 600 base pairs; SMAC KO: 750 base pairs 
 
Primer sets used for PCR amplification of Apaf-1 and GAPDH were as follows. 
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Apaf-1: Forward 5′ GAG GCA CAA TGG ATG CAA AGG 3′;  Reverse 5′ GGC TGC 
TCG TTG ATA TTG AGT GG 3′ 
GAPDH: Forward 5′ CCA TGG AGA AGG CTG GGG 3′;  Reverse 5′ CAA AGT TGT 
CAT GGA TGA CC 3′ 
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F. Figures and Legends 
 
Figure 2.1.  Etoposide induces a cytochrome c- and apoptosome-dependent apoptosis in 
sympathetic neurons.  A) Cultures of sympathetic neurons were either left untreated, treated 
with 20 µM etoposide, or treated with etoposide and the caspase inhibitor zVAD-fmk (50 
µM).  At various time points, cell survival was assessed by morphological criteria (healthy 
neurons remain intact and phase bright).  This method of assessing cell death correlates well 
with trypan blue exclusion (Fig. S1A) and calcein AM staining (Potts, Singh et al. 2003).  
Data shown are mean +SEM of three experiments.  Photographs show untreated or 
etoposide-treated sympathetic neurons at 60 hours.  B) Cultures of sympathetic neurons were 
treated with 20 uM etoposide for various time points, and the status of cytochrome c in these 
neurons was examined by immunocytochemical techniques.  Neurons showing a punctate 
staining pattern have maintained cytochrome c in the mitochondria, whereas neurons 
showing a loss of staining have released cytochrome c from the mitochondria.  
Approximately 100 neurons per condition were counted to determine the status of 
cytochrome c.  C)  Sympathetic neurons isolated from Apaf-1-deficient mice or their 
wildtype littermates were treated with 20 µM etoposide and cell survival was assessed as 
described above.  D) Sympathetic neuronal cultures isolated from XIAP+/+ or XIAP-/- mice 
were injected with cytochrome c and rhodamine dextran dye (Rhod) to mark injected cells, or 
rhodamine alone.  Wildtype sympathetic neurons (XIAP+/+) were also treated with etoposide 
(20 uM) for 24 hrs or left untreated and then injected with cytochrome c and rhodamine 
dextran dye (Rhod), or rhodamine alone.  Cell survival of these neurons was then assessed at 
various time points following injection. 
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Figure 2.2.  Development of competence by etoposide is independent of XIAP degradation, 
and requires protein synthesis.  A) Protein levels of XIAP were examined from whole cell 
lysate of sympathetic neurons maintained in NGF (+NGF), deprived of NGF (-NGF) for 24 
hours, or treated with 20 µM etoposide (+NGF +Etop) for 24 hours.  Levels of LDH were 
also examined as a loading control.  B) Quantitation of XIAP levels (mean + SEM of three 
experiments) in NGF-deprived and etoposide-treated neurons at 24 and 48 hours as compared 
to NGF maintained neurons is shown and is normalized to LDH.  C)  Cycloheximide (CHX) 
(1 µg/ml) treated wildtype sympathetic neurons, or neurons isolated from Bax-deficient mice 
were deprived of NGF for 24 hours.  Cells were then injected with 10 mg/ml cytochrome c 
along with rhodamine dextran or with rhodamine dextran dye alone.  At each time point after 
injections, the number of microinjected cells that remained viable was determined and 
expressed as a percentage of the total number of microinjected cells.  D) CHX (1 µg/ml) 
treated wildtype sympathetic neurons, or neurons isolated from Bax-deficient mice were 
treated with etoposide (20 µM) for 24 hours.  Cells were then injected with 10 mg/ml 
cytochrome c along with rhodamine dextran or with rhodamine dextran dye alone.  At each 
time point after injections, viable cells were quantified as in (C).  Results shown are a mean 
(+ SEM) for three experiments with 70-100 cells injected in each experiment. 
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Figure 2.3.  Etoposide treatment results in an increase in Apaf-1 protein and mRNA in 
sympathetic neurons.  A) Sympathetic neuronal cultures were either left untreated (+NGF), 
deprived of NGF (-NGF) or treated with 20 µM etoposide (+NGF +Etop) for 24 hours.  Cells 
were collected and levels of Apaf-1 protein analyzed by Western blot.  LDH was used as a 
loading control.  Quantitation of Apaf-1 protein levels normalized to LDH following 
etoposide treatment at 24 and 48 hours is shown.  Data are mean (+SEM) for three 
independent experiments.  B)  Sympathetic neurons were either left untreated, or treated with 
20 etoposide for 24 hours.  Levels of Apaf-1 and GAPDH (loading control) mRNAs were 
examined by quantitative RT-PCR and expressed as a percentage of NGF maintained as 
normalized to GAPDH. Quantitation shown is mean (+SEM) for three independent 
experiments.   
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 Figure 2.4.  p53-deficient neurons develop competence in response to NGF deprivation but 
not etoposide.  A)  Cultures of sympathetic neurons from p53+/+ or p53-/- mice were treated 
with 20 µM etoposide.  At various time points, cell survival was assessed by morphological 
criteria (healthy neurons remain intact and phase bright).  Data are a mean +SEM for three 
experiments with greater than 100 cells counted in each experiment.  Representative 
photographs at 60 hours after etoposide treatment are shown.  Scale bars represent 50 µm.  
B)  p53+/+ or p53-/- sympathetic neurons were treated with etoposide for 24 hours.  Cells 
were then microinjected with cytochrome c (10 mg/ml) alone or cytochrome c and SMAC (1 
mg/ml) together protein along with rhodamine dye, or rhodamine alone.  Cell survival was 
assessed at various time points as indicated.  C)  p53+/+ or p53-/- sympathetic neurons were 
deprived of NGF in the presence of cycloheximide (1 µg/ml) for 24 hours.  Cells were then 
microinjected with cytochrome c protein (10 mg/ml) along with rhodamine dye, or 
rhodamine alone.  Cell survival was assessed at various time points as indicated.  
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Figure 2.5.  p53 links Apaf-1 induction with XIAP inactivation during DNA damage-
induced neuronal apoptosis.  A)  p53+/- or p53-/- sympathetic neurons were either left 
untreated, or treated with etoposide (20 µM) for 24 hours.  Cells were then collected and 
Apaf-1 protein levels analyzed by Western blot.  Tubulin is used as a loading control. These 
data are representative of multiple experiments. B) p53-/- sympathetic neurons were injected 
with either a plasmid encoding Apaf-1 (200 ng/µl) along with EGFP (50 ng/µl), or empty 
vector (200 ng/µl) along with EGFP (50 ng/µl) and allowed to express DNAs for 24 hours.  
Cells were then treated with 20 µM etoposide for 24 hours (a time at which endogenous 
cytochrome c is retained in the mitochondria; Fig. S2), after which GFP expressing cells 
were injected with either cytochrome c protein (10 mg/ml) along with rhodamine, or 
rhodamine alone.  Cell survival of double injected cells was assessed by morphological 
criteria at the indicated time points. Data are a mean + SEM of three independent 
experiments with 70-100 cells injected per experiment.  Note that the data represented with 
open and filled circles are closely overlapping. 
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Figure 2.6.  Distinct SMAC-independent mechanisms by which XIAP is relieved in NGF 
deprivation and DNA damage models of neuronal apoptosis.  A)  While both NGF 
deprivation and DNA damage activate a pathway which releases cytochrome c from the 
mitochondria, the mechanisms by which these two stimuli induce competence and overcome 
XIAP’s inhibition of caspases are distinct.  NGF Deprivation selectively degrades XIAP, 
while DNA damage overcomes XIAP activity via a p53-mediated induction of Apaf-1.  B) 
Cultures of sympathetic neurons isolated from SMAC -/- or wildtype mice were either left 
untreated or treated with 20 µM etoposide.  Shown is quantitation of cell survival at various 
time points.  
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Supplemental Figure 2.1.  Assessment of cell death by multiple criteria.  A) Sympathetic 
neurons were treated with 20 uM etoposide for various time points.  For assessment of cell 
death by cell morphology, cells with intact phase bright cell bodies are counted as alive.  For 
trypan blue staining, cells were incubated in a 0.04 % trypan blue solution for 5 min and the 
number of cells that excluded the trypan blue dye was counted. B) Sympathetic neurons were 
treated with etoposide for 36 hours, followed by staining with Annexin V and Propidium 
Iodide (PI) as described in the Methods section.  Photographs depict healthy Annexin V 
negative, PI negative cells (left hand column), Annexin V positive, PI negative cells (middle 
column), and Annexin V positive, PI positive cells (right column).    
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Supplemental Figure 2.2.  Cytochrome c release by etoposide is inhibited in p53-deficient 
neurons.  p53+/+ or p53-/- sympathetic neurons were treated with etoposide (20 uM) for 24 
or 36 hours, and the status of cytochrome c in these neurons was examined by 
immunohistochemical techniques.  Neurons showing a punctate staining pattern have 
maintained cytochrome c in the mitochondria, whereas neurons showing a loss of staining 
have released cytochrome c from mitochondria.  Approximately 100 neurons per condition 
were counted to determine the status of cytochrome c.  
 72
%
 C
yt
 c
 re
le
as
e
 fr
om
 m
ito
ch
on
dr
ia
24 hrs 36 hrs
p53 +/+
p53 -/-
Supplemental Figure 2.2
73
  
 
 
Supplemental Figure 2.3.  Inactivation of XIAP is sufficient to permit p53-/- neurons to 
undergo cytochrome c-mediated apoptosis.  p53+/+ or p53-/- sympathetic neurons were 
microinjected with cytochrome c protein (10 mg/ml), or cytochrome c along with mature 
SMAC protein (1 mg/ml), or SMAC alone.  At various time points following injection, cells 
survival was assessed by morphological criteria. Data are a mean + SEM of three 
independent experiments with 70-100 cells injected per experiment. 
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Supplemental Figure 2.4.  Apaf-1 induction is the only step required by etoposide to 
sensitize p53-deficient neurons to cytochrome c.  p53-/- sympathetic neurons were injected 
with either a plasmid encoding Apaf-1 (200 ng/µl) along with  EGFP (50 ng/µl), or empty 
vector (200 ng/µl) along with EGFP (50 ng/µl).  After 24 hours, GFP expressing cells were 
injected with either cytochrome c protein along with rhodamine, or rhodamine alone.  Cell 
survival of double injected cells was assessed by morphological criteria at the indicated time 
points.   Data are a mean + SEM of three independent experiments with 70-100 cells injected 
per experiment. 
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Supplemental Figure 2.5.  Timecourse of etoposide-induced death in wildtype and XIAP-
deficient neurons.  Sympathetic neurons isolated from XIAP-/-, or their wildtype littermates 
(XIAP+/+) were treated with 20 uM etoposide (+NGF+Etop), or left untreated (+NGF).  Cell 
survival was assessed by morphological criteria at various time points.    
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III.  CHAPTER THREE: 
 
Glucose Metabolism Inhibits Apoptosis in Neurons and Cancer Cells by Redox 
Inactivation of Cytochrome c 
 
 
 
A. Abstract 
 
Neurons and cancer cells utilize glycolysis extensively, yet the precise advantage of this 
adaptation remains elusive.  Here we show that these cells strictly inhibit cytochrome c-
mediated apoptosis by a mechanism dependent on glucose metabolism.  We report that the 
proapoptotic activity of cytochrome c requires its oxidation and that this is accomplished by 
increases in intracellular ROS following an apoptotic insult.  In healthy neurons and cancer 
cells, cytochrome c is reduced and held inactive by intracellular glutathione (GSH) generated 
as a result of glucose metabolism by the pentose phosphate pathway. These results uncover a 
striking similarity in apoptosis regulation between neurons and cancer cells and provide 
insight into an adaptive advantage offered by the Warburg effect for cancer cell evasion of 
apoptosis and for long-term neuronal survival. 
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B. Introduction 
Apoptosis is a genetically regulated process that is essential for the development of the 
organism, but its dysregulation can lead to neurodegenerative disorders as well as cancer 
(Yuan and Yankner 2000; Green and Evan 2002).  A critical event in the apoptotic pathway 
is the release of cytochrome c from the mitochondria.  In healthy cells, cytochrome c resides 
in the mitochondrial intermembrane space where it serves as a redox carrier for the electron 
transport chain.  However, in response to many apoptotic stimuli, cytochrome c is released 
into the cytosol where it can initiate the formation of the apoptosome complex, leading to 
caspase activation and subsequent cell death (Wang 2001).  Emerging evidence indicates that 
cells such as postmitotic neurons, which last the lifetime of the organism, as well as cancer 
cells, which must overcome a cell death response, both strictly inhibit the apoptotic pathway 
(Wright and Deshmukh 2006).  Interestingly, despite the striking morphological and 
functional differences between neurons and cancer cells, both depend on glycolysis as their 
primary source of energy (Warburg 1956; Schubert 2005).  Here we examined whether the 
mutual reliance on glycolysis was of critical importance to the increased resistance to 
apoptosis in neurons and cancer cells. 
 
C. Results 
   We assessed the ability of endogenous cytochrome c to activate apoptosis in 
sympathetic neurons by using truncated Bid (tBid).  Full length Bid is cleaved intracellullarly 
into tBid in response to certain apoptotic stimuli, where it then acts as a potent inducer of 
cytochrome c release from mitochondria (Esposti 2002).  While expression of tBid-GFP 
plasmid DNA in mouse embryonic fibroblasts (MEFs) resulted in rapid and complete 
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apoptosis, nerve growth factor (NGF)-maintained sympathetic neurons remained remarkably 
resistant to expression of tBid-GFP (Fig. 3.1A).  Sympathetic neurons are known to be 
resistant to exogenously microinjected cytochrome c because of the strict inhibition of 
caspases by XIAP.  In contrast to wildtype neurons, XIAP-deficient sympathetic neurons are 
sensitive to microinjection of exogenous cytochrome c (Potts, Singh et al. 2003).  However, 
we were surprised to find that the release of endogenous cytochrome c with tBid was 
incapable of inducing apoptosis even in XIAP-deficient neurons (Fig. 3.1B).  This inability to 
induce apoptosis is not a defect in tBid itself, as expression of tBid in sympathetic neurons 
induced potent release of cytochrome c from the mitochondria (Fig. 3.1C).  Thus, in NGF-
maintained neurons, the release of endogenous cytochrome c was incapable of inducing 
apoptosis even in the absence of XIAP.  To focus on this unexpected XIAP-independent 
mechanism of postcytochrome c regulation, we conducted all following experiments in 
neurons isolated from XIAP-deficient mice. 
 Despite the resistance of neurons to direct cytochrome c release by tBid, sympathetic 
neurons readily undergo cytochrome c-mediated cell death in response to multiple apoptotic 
stimuli (Neame, Rubin et al. 1998; Vaughn and Deshmukh 2007).  Thus, apoptotic stimuli 
must render endogenous cytochrome c capable of activating apoptosis in neurons.  Indeed, 
NGF deprivation as well as DNA damage with etoposide sensitized sympathetic neurons to 
apoptosis induced by tBid-mediated cytochrome c release (Fig. 3.1D, Supplemental Fig. 
3.1A).  Since tBid may cause the release of multiple factors from the mitochondria, we 
examined whether this observed effect was a direct result of sensitization to cytochrome c.  
Indeed, injection of cytochrome c in NGF-deprived or DNA-damaged neurons (at a time 
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point prior to endogenous cytochrome c release) also showed increased sensitivity (Fig. 3.1E, 
Supplemental Fig. 3.1B). 
To be apoptotically active, cytochrome c must exist as a holoenzyme complete with its 
heme prosthetic group (Yang, Liu et al. 1997).   Results from in vitro studies that have 
examined whether the redox state of cytochrome c affects its apoptotic activity remain 
controversial.  While some show that oxidized cytochrome c is more apoptotically active, 
others suggest that the reduced form can also function effectively (Kluck, Martin et al. 1997; 
Hampton, Zhivotovsky et al. 1998; Pan, Voehringer et al. 1999; Hancock, Desikan et al. 
2001; Chen, Crosby et al. 2003; Suto, Sato et al. 2005).  To determine whether the 
intracellular redox environment affects the sensitivity of intact neurons to cytochrome c, we 
treated neurons with either low levels of hydrogen peroxide (H2O2) to create a more oxidized 
environment, or cell permeable reduced glutathione (GSH) to make the environment more 
reduced.  Neurons injected with 2.5 ug/ul cytochrome c exhibit substantial death only 10-16 
hrs after the injections (Fig. 3.2A, B).  However, H2O2 greatly increased the sensitivity of 
neurons to injected cytochrome c (Fig. 3.2A) while neurons treated with GSH are resistant 
(Fig. 3.2B).  These results show that in intact cells, the redox environment has a dramatic 
affect on the ability of cytochrome c to promote apoptosis.  
As changes in the redox environment can have widespread affects, we determined 
whether the ability of the reduced cellular environment to inhibit cytochrome c-mediated 
apoptosis is a result of the specific inactivation of cytochrome c.   Incubation of cytochrome 
c with cytochrome c reductase rendered this now reduced cytochrome c (Supplemental Fig. 
3.2) ineffective for promoting apoptosis in injected neurons (Fig. 3.2C). In addition, we 
generated both wildtype cytochrome c protein, and a N52I mutant of cytochrome c which has 
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increased stability, making it less prone to oxidation (Doyle, Waldner et al. 1996).  Injection 
of the N52I mutant cytochrome c into sympathetic neurons induced significantly less 
apoptosis than did wildtype cytochrome c (Fig. 3.2D).  This mutant protein also exhibited a 
diminished ability to activate caspases in an in vitro assay (Supplemental Fig. 3.3).    
The observation that cytosolic cytochrome c requires an oxidized cellular environment 
to be proapoptotic leads to two predictions.  First, that the ability of tBid-induced cytochrome 
c release to promote apoptosis in MEFs but not in NGF-maintained neurons could be due to a 
marked difference in their redox environment.  Consistent with this, we find that the average 
intensity of the redox-sensitive dye 5- (and-6)-chloromethyl-2’, 7’-
dichlorodihydrofluorescein diacetate (CM-H2 DCFDA) was 5 fold less in sympathetic 
neurons as compared to MEFs, indicating reduced levels of reactive oxygen species (ROS) in 
sympathetic neurons (Supplemental Fig. 3.3A).  Second, that NGF deprivation, which 
sensitizes neurons to cytochrome c-induced death, may result in an increased oxidized 
cellular environment.  Indeed, CM-H2 DCFDA intensity was elevated 2.5 fold after NGF 
deprivation in neurons (Supplemental Fig. 3.3B; (Greenlund, Deckwerth et al. 1995; 
Kirkland and Franklin 2001)).  This increase in ROS following NGF deprivation was 
important to permit cytochrome c-mediated apoptosis as addition of GSH inhibited the ability 
of NGF deprivation to sensitize neurons to cytochrome c release (Fig 3.2E).  Importantly, we 
examined whether the levels of ROS accumulating after NGF deprivation were sufficient to 
oxidize cytochrome c.  While cytochrome c added to NGF-maintained neuronal lysates 
remained in a reduced state, NGF-deprived neuronal lysate was able to oxidize cytochrome c, 
as measured by a decrease in absorbance peak at 550 nm (Fig. 3.2F). 
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GSH is one of the most prevalent cellular reducing agents and maintains redox 
homeostasis by scavenging ROS.  We found that intracellular GSH is necessary for 
maintaining cytochrome c in an inactive state in NGF-maintained neurons, as inhibition of 
GSH with Diethyl Maleate (DEM) leads to an increase in ROS and sensitizes neurons to 
cytosolic cytochrome c (Fig. 3.3A,B).  Levels of GSH are maintained in cells by reduced 
nicotinamide adenine dinucleotide phosphate (NADPH), which is generated when glucose is 
metabolized via the pentose phosphate pathway (Kaplowitz, Aw et al. 1985).  We examined 
whether the pentose phosphate pathway was important for regulating the redox status of 
neurons, and thus cytochrome c-mediated apoptosis.  Neurons treated with the pentose 
phosphate pathway inhibitor, dehydroepiandrosterone (DHEA), accumulated high levels of 
ROS and became sensitive to endogenous cytochrome c release with tBid (Fig. 3.3C,D).  
This effect was not unique to DHEA as another inhibitor of the pentose phosphate pathway, 
6-anicotinamide (6-AN) was also able to sensitize neurons to cytochrome c release (Fig. 
3.3D).  Together, these data show how glucose metabolism via the pentose phosphate 
pathway promotes neuronal survival by maintaining GSH levels and directly restricting 
cytochrome c-mediated apoptosis. 
Like neurons, many cancer cells are known to depend predominantly on glycolysis for 
ATP generation, a phenomenon known as the Warburg effect (Warburg 1956).  To 
investigate whether increased glycolysis in cancer cells directly regulates apoptosis at the 
point of cytochrome c, we first examined the sensitivity of cancer cells to cytosolic injection 
of cytochrome c.  Cytochrome c was injected in the presence of SMAC to eliminate the 
activity of IAPs that are known to block caspase activation in many cancer cells (Verhagen 
and Vaux 2002), thus focusing on IAP-independent mechanisms of cytochrome c regulation.  
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While normal cells (MEFs, Human Dermal Fibroblasts-HDFs) readily underwent apoptosis 
in response to cytosolic cytochrome c, multiple cancer cells tested showed an increased 
resistance (Fig. 3.4A).  Strikingly, the sensitivity to cytochrome c correlated with the levels 
of intracellular GSH in these cancer cells, with the highly resistant hepatoma cell line JM2 
containing as much as 5 fold more intracellular GSH than noncancerous cells (Fig. 3.4B).   
We examined whether enhanced glycolysis and the pentose phosphate pathway in HeLa 
and JM2 cancer cells contributes to cellular redox homeostasis, and thus resistance to 
cytochrome c.  Indeed, addition of the pentose phosphate inhibitor DHEA increased ROS 
levels and specifically rendered these cancer cells sensitive to cytosolic cytochrome c (Fig 
3.4. C,D).  Importantly, reducing glycolysis by glucose deprivation also resulted in a similar 
increase in sensitivity to cytochrome c (Fig. 3.4E).  Together, these results show that the 
ability of cytochrome c to induce apoptosis is strictly regulated by its redox state and that 
glycolysis flux is a critical regulator of cytochrome c-mediated apoptosis. 
 
D. Discussion 
By coupling the proapoptotic activity of cytochrome c to the pentose phosphate 
pathway, cells which have increased glycolytic flux, such as neurons and cancer cells, are 
able to effectively maintain a restrictive environment for cytochrome c-mediated apoptosis.  
Such a regulation would be of particular physiological importance for neurons that have 
limited regenerative potential and survive long term, and advantageous to cancer cells in 
evading apoptosis.  Flux through the pentose phosphate pathway is likely to inhibit apoptosis 
in multiple scenarios.  For example, upregulation of TIGAR following p53 activation by 
DNA damage was recently shown to engage the pentose phosphate pathway and promote cell 
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survival (Bensaad, Tsuruta et al. 2006).  Overexpression of glucose-6-phosphate 
dehydrogenase is also shown to promote tumor formation by increasing GSH through 
pentose phosphate pathway (Kuo, Lin et al. 2000).  Our results suggest that a specific 
mechanism by which this could inhibit apoptosis is through direct inactivation of cytochrome 
c.      
Although exactly how a change in the redox status can influence the apoptotic activity 
of cytochrome c is unknown, it is likely that the redox status affects cytochrome c binding to 
its downstream apoptotic effector, Apaf-1.  While the overall structural differences between 
oxidized and reduced cytochrome is not substantial, the oxidation state does have a more 
pronounced affect on the orientation specific residues, such as Lysine 72 (Kar, Sherman et al. 
1994).  Interestingly, modification of Lysine 72 is an important factor in determining whether 
cytochrome c from different species will be proapoptotic (Kluck, Ellerby et al. 2000).  
Although maintenance of redox homeostasis is a primary function of the pentose 
phosphate pathway, flux through this pathway may also inhibit apoptosis at other points.  For 
example, NADPH production through the pentose phosphate pathway maintains caspase-2 in 
an inactive state in Xenopus egg extracts by a mechanism independent of GSH synthesis 
(Nutt, Margolis et al. 2005). 
Neurons undergoing cytochrome c-mediated apoptosis must overcome multiple blocks 
in order to undergo cell death.  We have shown previously that endogenous XIAP is a potent 
inhibitor of cytochrome c-mediated apoptosis in neurons (Potts, Singh et al. 2003), and here, 
that endogenous cytochrome c itself is incapable of inducing apoptosis in NGF-maintained 
neurons.  In response to developmental apoptosis after trophic factor deprivation, these 
neurons not only exhibit degradation of XIAP to allow for caspase activation, but also a 
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marked decrease in glucose uptake and increase in ROS (Supplemental Fig. 3.3B) 
(Deckwerth and Johnson 1993; Greenlund, Deckwerth et al. 1995; Kirkland and Franklin 
2001; Potts, Singh et al. 2003) which can activate cytochrome c and permit apoptosis. 
Increases in intracellular ROS as well as mitochondrial damage are commonly seen 
during aging and associated with apoptotic cell death in many neurodegenerative diseases, 
including Parkinson’s Disease (Carney, Smith et al. 1994; Squier 2001; Rego and Oliveira 
2003).  Our results provide mechanistic insight into how even a modest increase in ROS 
would prime neurons to undergo apoptosis in response to otherwise potentially non-lethal 
events of mitochondrial damage and cytochrome c release (Deshmukh, Kuida et al. 2000). 
Neurons and cancer cells are indeed strikingly distinct by most criteria.  Different 
cancer cells themselves appear to inhibit the apoptotic pathway at different points. However, 
these results bring into focus the possibility that the multiple mechanisms evolved by neurons 
to restrict apoptosis would be the same ones adapted by some mitotic cells during their 
progression to becoming cancerous. 
 
E. Materials and Methods: 
Reagents.  
All reagents were purchased from Sigma (St Louis, MO, USA) or Fisher Scientific 
(Pittsburgh, PA, USA) unless otherwise stated.  Collagenase and trypsin were purchased 
from Worthington Biochemical Corporation (Freehold, NJ, USA).  Recombinant SMAC 
protein was purified from bacteria as previously described (Potts, Singh et al. 2003) and used 
at a concentration of 1.5 mg/ml.  MEFs were a kind gift provided by Dr. Douglas Green (St. 
Jude’s Children’s Research Hospital, Memphis, TN).  HDFs and HeLa cells were obtained 
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from UNC Tissue Culture Facility, and JM2 cells were a kind gift of Dr. Ekhson 
Holmuhamedov (UNC, Chapel Hill, NC).  XIAP-/- mice were a kind gift from Dr. Craig 
Thompson (University of Pennsylvania, Philadelphia, PA). 
 
Sympathetic neuronal cultures. 
Primary sympathetic neurons were dissected from the superior cervical ganglia of postnatal 
day 0-1 mice from wildtype ICR or XIAP-deficient C57BL/6 mice and maintained in culture 
as described previously (Deshmukh, Kuida et al. 2000).  Cells were plated on collagen coated 
dishes at a density of 10,000 cells per well.  Neurons were grown for 4-5 days in NGF-
containing media before treating them with experimental conditions.  For NGF deprivation, 
cultures were rinsed three times with medium lacking NGF, followed by the addition of goat 
anti-NGF neutralizing antibody to this media.  Etoposide was used at a concentration of 20 
µM.  
 
Immunofluorescence analysis. 
The status of cytochrome c following expression of tBid-GFP (whether intact in the 
mitochondria or released) was examined by immunofluorescence.  Sympathetic neurons 
exhibit a punctate mitochondrial staining with anti-cytochrome c antibody, which is lost as 
cytochrome c is released from the mitochondria.  Briefly, cultured sympathetic neurons that 
had been expressing tBid for 24 hours were fixed in 4% paraformaldehyde and incubated 
overnight with anti-cytochrome c (556432, BD Biosciences), or anti-GFP (Cell Signaling) 
primary antibody followed by a 2 hour incubation with anti-mouse Cy3 and anti-Chicken 
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Alexa 488 secondary antibody (Jackson Labs).  Nuclei were stained with Hoechst 33258 
(Molecular Probes).  
 
Microinjection and quantitation of cell survival.  
Cells were injected with horse cytochrome c protein at a concentration of 2.5 ug/ul.  Horse 
cytochrome c (Sigma) is predominantly in an oxidized state (Supplemental Fig. 3.2).  
Immediately after injections, the number of rhodamine-positive cells were counted.  At 
various times after injections, the number of viable injected cells remaining was determined 
using the same counting criteria and expressed as a percentage of the original number of 
microinjected cells.  This method of assessing survival has correlated well with other cell 
survival assays such as trypan blue exclusion and staining with calcein AM (Potts, Singh et 
al. 2003). 
 In experiments involving microinjection of DNAs, 100 ng/ul of the tBid expressing 
plasmid, or EGFP vector in microinjection buffer was injected into the nucleus of neurons or 
MEFs.  To quantitate survival after injection, GFP-positive cells were counted 5 hours after 
injection as well as 24 hours following injection.  Cell survival is expressed as a ratio of 
viable GFP-positive cells at 24 hours post-injection over 5 hours post injection.  In 
experiments involving assessment of cell survival following tBid expression in the absence 
of NGF or presence of etoposide, neuronal cultures were deprived of NGF or treated with 
etoposide for 12 hrs followed by microinjection with tBid-GFP or EGFP alone.  Cell survival 
was expressed as a ratio of viable GFP-positive cells at 16 hours post-injection over 5 hours 
post-injection. 
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ROS measurement.  
The redox-sensitive dye CM-H2 DCFDA (Molecular Probes) was used to measure ROS 
levels in sympathetic neuronal cultures using the protocol described previously (Kirkland and 
Franklin 2001).  CM-H2 DCFDA is non-fluorescent when reduced and following 
permeabilizing of the cell is cleaved by esterases and is trapped in the cell where oxidation 
converts it to a fluorescent form.  After treatment of cells with various experimental 
conditions, cells were incubated with 10 µM CM-H2 DCFDA for 20 minutes followed 
rinsing 3 times in PBS.  Fluorescent intensity of cells was represented as an image, and or 
quantitated by measuring pixel intensity in a 50 µm2 area within individual soma using 
Metamorph software. 
 
Cytochrome c redox status. 
The redox status of cytochrome c was assessed by monitoring the absorbance of horse 
cytochrome c (40 µM) at 550 nm on Nanodrop spectrophotometer.  For experiments 
involving analysis of redox activity of cytochrome c following NGF deprivation, sympathetic 
neurons were plated at a density of 100,000 cells, and maintained in NGF, or deprived of 
NGF for 12 hours.  Neuronal lysate was collected and incubated with reduced cytochrome c 
(reduced with 0.5 mM DTT) prior to analysis as described above. 
 
Reduced glutathione measurements. 
Measurements of intracellular GSH were carried out according to a modification of the 
method of Tietze (Tietze 1969).  Briefly, cultured cells were washed three times in PBS 
followed by lysis in 3% perchloric acid for 15 minutes at 4°C.  After centrifugation, 
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supernatants were immediately measured for GSH content by assessing the colorimetric 
change of 600 µM 5,5’-dithiobis (nitrobenzoic acid) (DTNB) at 412 nm.  GSH standards 
were prepared fresh for each experiment in 0.01N HCl.  The perchloric acid pellet was 
resuspended in 1N NaOH, and the solubilized protein measured by Biorad Protein Assay 
with BSA as a standard.  GSH was normalized to total cell protein.   
 
Image acquisition and processing. 
All images were acquired by a Hamamatsu ORCA-ER digital B/W CCD camera mounted on 
a Leica inverted fluorescence microscope (DMIRE 2).  The image acquisition software was 
Metamorph version 5.0 (Universal Imaging Corporation).  Images were scaled down and 
cropped in Adobe Photoshop to prepare the final figures. 
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F. Figures and Legends 
 
 
Figure 3.1.  Endogenous cytochrome c release is incapable of inducing apoptosis in NGF-
maintained sympathetic neurons.  A) Cultures of MEFs or sympathetic neurons were injected 
with tBid-GFP, or GFP plasmid.  Cell survival was quantified by cell morphology and 
expressed as a percentage of alive and healthy green cells at 24 hrs compared to 5 hrs post-
injection.  * represents no MEF survival.  B) XIAP -/- sympathetic neurons or wildtype 
littermates were injected with EGFP or tBid-GFP, and cell survival was quantified as in (A).  
C)  tBid-GFP was injected into sympathetic neurons, and allowed to express for 24 hrs.  
Cells were fixed, and the status of cytochrome c analyzed by immunofluorescence.  D)  
XIAP-/- sympathetic neurons were either maintained in NGF-containing media, or deprived 
of NGF for 12 hrs, followed by injection with EGFP or tBid-GFP.  Cell survival was 
quantified by cell morphology and expressed as a percentage of alive and healthy green cells 
at 16 hrs compared to 5 hrs post-injection.  E) XIAP-/- sympathetic neurons were deprived of 
NGF for 12 hrs followed by injection with rhodamine alone, or cytochrome c protein along 
with rhodamine to mark injected cells.  Cell survival was assessed at various time points 
following injection.  Error bars represent ±SEM of three independent experiments. 
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Figure 3.2.  Oxidation of cytochrome c increases its apoptotic activity.  A) XIAP-/-
sympathetic neurons were treated with 20-50 µM of H2O2 for 20 minutes, followed by 
injection with cytochrome c protein and rhodamine, or rhodamine dye alone.  Cell survival 
was assessed at various time points following injection. B) XIAP-/- sympathetic neurons 
were treated with 10 mM GSH ethyl ester for 12 hrs, followed by injection of cytochrome c 
along with rhodamine, or rhodamine alone.  Cell survival was assessed as in (A).  C)  
Cytochrome c was incubated with 10 Units/ml of cytochrome c reductase (NADPH), 
followed by injection into sympathetic neurons (XIAP-/-).  Cell survival was assessed at 
various time points following injection.  D)  XIAP-/- sympathetic neurons were injected with 
recombinant wildtype (WT) or N52I cytochrome c (4 µg/ul) and assessed for survival after 4 
hrs. E)  XIAP-/- sympathetic neurons were deprived of NGF for 12 hrs in the presence of 
10mM GSH, followed by injection with EGFP or tBid-GFP constructs.  Cell survival was 
quantified by cell morphology and expressed as a percentage of alive and healthy green cells 
at 16 hrs compared to 5 hrs post-injection.  F)  Reduced cytochrome c was added to neuronal 
extracts, and A550 was measured.  Results are mean (±SEM) of three independent 
experiments.   
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Figure 3.3.  Role of the glycolytic pentose phosphate shunt in cytochrome c-mediated 
apoptosis.  A) Average ROS levels in sympathetic neurons were observed by fluorescence 
intensity of the redox-sensitive dye CM-H2DCFDA following 30 min of GSH depletion with 
0.1 mM DEM.  B) XIAP-/- sympathetic neurons were treated with 0.1 mM DEM for 30 min 
followed by injection of cytochrome c and rhodamine, or rhodamine dye alone.  C) Average 
ROS levels were observed as in (A) following inhibition of the Pentose Phosphate Pathway 
with 200 µM DHEA for 24 hrs.  D) XIAP -/- sympathetic neurons were treated with 200 µM 
DHEA.  After 6 hrs, neurons were injected with tBid-GFP or EGFP constructs alone.  Cell 
survival was expressed as a percentage of healthy green cells at 16 hrs compared to 5 hrs 
post-injection.  Error bars represent ±SEM. 
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Figure 3.4. Cancer cells exhibit glycolysis-meditated protection from cytochrome c.  A) 
MEFs, HDFs or various cancer cell lines were injected with cytochrome c and SMAC protein 
and cell survival was assessed after 30 minutes. B) GSH content was measured in normal 
mitotic cells (MEFs, HDFs) as well as cancer cell lines.  GSH content is expressed as a ratio 
of GSH to total cellular protein. C) Average ROS levels in HeLa cells measured by 
fluorescence of CM-H2DCFDA in the absence or presence of the pentose phosphate pathway 
inhibitor, DHEA (200 µM) for 6 hrs.  D) The pentose phosphate pathway was inhibited with 
200 µM DHEA in JM2 as well as HeLa cells for 6 hrs by addition of 200 µM DHEA, 
followed by injection of cytochrome c and SMAC protein.  Cell survival was assessed at 
various time points.  E) JM2 and HeLa cells were deprived of glucose for 16 hrs followed by 
injection with cytochrome c and SMAC, and assessed for survival at various time points. 
Images are representative of JM2 cells at 3 hrs following cytochrome c injection.   Error bars 
represent ±SEM. 
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Supplemental Figure 3.1.  DNA damage sensitizes neurons to cytochrome c-mediated 
apoptosis.  A) XIAP-/- sympathetic neurons were treated with 20 µM etoposide for 12 hrs, 
followed by injection of tBid-GFP or EGFP plasmids.  Cell survival was assessed by 
morphology by quantifying the number of viable GFP positive cells at 16 hrs compared to 5 
hrs post-injection. B)  XIAP-/- sympathetic neurons were treated with 20 µM etoposide for 
12 hrs followed by injection with cytochrome c and rhodamine, or rhodamine alone.  Cell 
survival was assessed at multiple time points. 
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Supplemental Figure 3.2.  GSH and cytochrome c reductase convert oxidized cytochrome c 
to reduced cytochrome c.  40 µM bovine cytochrome c was incubated with either 10 mM 
glutathione ethyl ester or 10 units/ml cytochrome c reductase (NADPH) for 15 minutes, 
followed by measurement at Abs550. 
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Supplemental Figure 3.3.  N52I Cytochrome c has diminished ability to activate caspases in 
vitro.  A)  Cytosolic extracts from MEFs were assessed for caspase activation after the 
addition of Wildtype or N52I mutant cytochrome c (2.5 µM) by measuring the cleavage of 
the fluorogenic substrate, DEVD-afc.  B)  Western blot showing the status of caspase-9 and 
caspase-3 cleavage in cytosolic lysate after the addition of cytochrome c as described in (A).  
Actin is shown as loading control. 
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Supplemental Figure 3.4.  ROS levels in MEFs, and sympathetic neurons after NGF 
deprivation.  A)  MEFs were co-cultured with sympathetic neurons, followed by incubation 
with 10 µM CM-H2DCFDA redox-sensitive dye.  Fluorescent intensity was measured in a 50 
µm2 area within individual soma and quantified using Metamorph software.  B) XIAP-/- 
sympathetic neurons were maintained in NGF, or deprived of NGF for 24 hrs, followed by 
incubation with CM-H2DCFDA.  Fluorescent intensity was quantified as in (A). 
 108
Fo
ld
 ∆
C
M
-H
2D
C
FD
A
 In
te
n
si
ty
Sympathetic 
    neurons
+ NGF
A B
-NGFMEFs
Fo
ld
 ∆
C
M
-H
2D
C
FD
A
 In
te
n
si
ty
Supplemental Figure 3.4
109
IV. CHAPTER FOUR: 
Age Dependent Changes in the Regulation of the Apoptosome in Neurons 
 A. Abstract 
Our data in PC12 cells and primary sympathetic neurons suggests that as mitotic cells 
become postmitotically differentiated, they more stringently regulate caspase activation and 
apoptosis.  To examine whether this phenomenon extends to neurons of the developing brain, 
we examined whether the cerebellum exhibits age-dependent changes in the regulation of 
cytochrome c induced apoptosis.  Here, we show that cytochrome c was sufficient to activate 
caspases in extracts from postnatal day five (P5) but not P13 and P19 cerebellum.  The 
resistance of mature P19 cerebellar neurons to cytochrome c correlated with a dramatic 
reduction in the levels of all three apoptotic mediators, Apaf-1, caspase-9 and caspase-3.  In 
contrast, P13 cerebellar neurons exhibited remarkable resistance to cytochrome c despite 
maintaining high levels of these proapoptotic proteins.  Complementation experiments 
identified a specific and marked defect in Apaf-1 activity in P13 extracts.  Interestingly, the 
activity of Apaf-1 in the developing cerebellum correlated with its phosphorylation, while 
inactive Apaf-1 in P13 brain remained unphosphorylated. 
A stricter control of apoptosis in neurons as they mature is arguably beneficial for these 
postmitotic cells to survive the lifetime of the organism.  Our data define three specific stages 
in which developing neurons exhibit an age-dependent change in the regulation of apoptosis 
and identify a potentially novel mechanism by which Apaf-1 function is regulated in 
maturing neurons.   
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B. Introduction 
A clear understanding of how the apoptotic pathway is regulated is of particular 
importance in the nervous system.  During development, neuronal elimination is crucial to 
ensure the proper setup of the nervous system, however, aberrant loss of neurons can result in 
neurodegenerative disease. 
A critical trigger of the initrinsic pathway of apoptosis is the release of cytochrome c 
from the mitochondria.  Once in the cytosol, cytochrome c binds to and induces a 
conformational change in the protein, Apaf-1, causing it to oligimerize.  Oligimerized Apaf-1 
then recruits and activates caspase-9, which can then go on to activate the executioner 
caspases of apoptosis such as caspase-3 and caspase-7.   
These major components of the apoptotic pathway have been well characterized in 
mitotic cells and biochemical assays.  However, recent work by our lab has suggested that 
sympathetic neurons more strictly regulate the apoptotic pathway than do mitotic cells.  For 
example, addition of cytochrome c (by either microinjection or addition to cytosolic extracts) 
to the cytosol of mitotic cells such as fibroblasts results in rapid caspase activation and 
apoptosis (Liu, Kim et al. 1996; Li, Srinivasan et al. 1997; Brustugun, Fladmark et al. 1998; 
Juin, Hueber et al. 1999; Wright, Linhoff et al. 2004).  Whereas, microinjection of 
cytochrome c into the cytosol of differentiated sympathetic neurons is unable to initiate cell 
death (Deshmukh and Johnson 1998; Wright, Linhoff et al. 2004).  Here, we examine 
whether other postmitotic neurons, particularly those of the central nervous system (CNS), 
acquire similar brakes on the cytochrome c-mediated apoptotic pathway, and if so, by what 
mechanisms.     
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Cerebellar granule neurons (CGNs) are the most abundant neurons in the brain, 
comprising greater than 90% of cells in the cerebellum (Contestabile 2002).  CGN 
neurogenesis occurs largely postnatally.  In the mouse, CGNs lie in the external granule 
layer, and proliferate there during the first week following birth.  By the second postnatal 
week, they stop dividing, and migrate towards the inner graule layer of the cerebellum and 
differentiate (Hatten 1999).  
Apoptosis of cerebellar granule neurons occurs during the development of the 
cerebellum.  Although the exact stimulus that triggers this cell death is not well understood, 
these cells die in a caspase-dependent manner (Contestabile 2002).  In addition, caspase-
dependent apoptosis of CGNs is also seen as a result of various pathological stimuli (Ferrer 
1999; Tanaka, Momoi et al. 2000; Puig, Tortosa et al. 2001).  Here, we describe a novel 
mechanism by which neurons of the developing cerebellum becoming increasingly resistant 
to cytochrome c-mediated caspase activation as they differentiate.   
 
C. Results 
1. Cytochrome c is sufficient to induce caspase activation in P5 (mitotic), but not in 
P13 (postmitotic) cerebellar extracts 
To determine whether neurons of the CNS become resistant to cytochrome c-mediated 
apoptosis as they differentiate, cytosolic extracts were made from the cerebellum of mice at 
different stages of development and their ability to activate caspases as measured by the 
cleavage of the fluorogenic caspase substrate, DEVD-afc, with the addition of exogenous 
cytochrome c was assessed.  Indeed, we found that postnatal day five (P5) lysates readily 
activated caspases, while lysates made in a similar manner from the cerebellums of postnatal 
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day 13 (P13) and postnatal day 19 (P19) animals were unable to activate caspases upon the 
addition of cytochrome c (Fig. 4.1A).  Western analysis confirms this finding.  P5 lysates 
show potent caspase-9 as well as caspase-3 processing, while P13 and P19 lysates exhibit 
neither processed caspase-9 or caspase-3 after cytochrome c addition (Fig. 4.1B).   While 
these extracts were made from whole cerebellum, it is likely that these results most 
accurately represent the properties of CGNs, which make up over ninety percent of the 
neurons in the cerebellum.  To examine this directly, cytosolic lysates were made from CGNs 
isolated from P4 animals and left in culture for one day (equivalent of P5), or from CGNs 
cultured for nine days (P13 equivalent).  CGNs cultured for one day were competent to 
activate caspases upon the addition of cytochrome c, however CGNs equivalent of P13 were 
markedly resistant to cytochrome c (Fig. 4.1C).  Together, this data suggests that as 
cerebellar granule neurons differentiate and become postmitotic, they acquire a resistance to 
cytochrome c-mediated apoptosis.   
 
2. The inability of cytochrome c to induce apoptosis in P13 cerebellar extracts is 
not due to regulation by IAPs 
Previously, our lab has shown that postmitotic cells such as sympathetic neurons and 
cardiomocytes are resistant to cytochrome c-mediated caspase activation due to strict 
inhibition of caspases by the X-linked inhibitor of apoptosis protein (XIAP) (Potts, Singh et 
al. 2003; Potts, Vaughn et al. 2005).  To examine whether IAPs play a role in mediating the 
resistance of P13 cerebellum to cytochrome c, P13 cerebellar extracts were incubated with 
cytochrome c along with the IAP inhibitor SMAC.  Surprisingly, even in the presence of 
SMAC, where IAPs are inhibited, cytochrome c was unable to induce caspase activation in 
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P13 lysates (Fig 4.2A).  To confirm this, these extracts were analyzed by Western blot for 
caspase activation.  Even with the addition of excess SMAC, neither caspase-9 or caspase-3 
was processed in P13 cerebellar extracts treated with cytochrome c (Fig 4.2B).  In addition, 
lysates made from P19 animals are also unable to activate caspases with cytochrome c and 
SMAC.  Although these results suggest that XIAP is not important for the restriction of 
apoptosis in cerebellar neurons, cerebellar lysates made from XIAP deficient mice from a 
slightly earlier age (P10) exhibited an increase in caspase activation compared to wildtype 
littermates (Fig. 4.2C).  These data show that while XIAP mediates resistance in P10 
cerebellar neurons, as these neurons mature (P13 and older), they develop an IAP-
independent mechanism of resistance to cytochrome c.
 
3.  P13 cerebellar neurons exhibit a specific defect in Apaf-1 activity, despite 
maintaining high levels of Apaf-1 protein 
 We then asked whether the inability of the differentiating cerebellum (P13) to 
undergo apoptosis in response to cytochrome c was due to a defect in expression of one of 
the components of the apoptosome.  Despite the difference in apoptotic activity, we found 
that all components necessary for apoptosome activity (Apaf-1, caspase-9, and caspase-3) 
were present to similar levels in both P5 and P13 cerebellar lysates (Fig 4.3A). 
Since the IAP family of caspase inhibitors was not responsible for resistance of P13 
lysates to cytochrome c, we asked whether this resistance was mediated by an as yet 
unidentified inhibitor of apoptosome formation of caspase activation.  If this were the case, 
we would expect that mixing activateable P5 lysates with lysate from P13 would inhibit the 
overall activity of the P5 lysate.  Surprisingly, a mixture of P5 and P13 cerebellar lysate 
 115
activated quite readily, arguing against the presence of a potent inhibitor of caspase 
activation in P13 lysates (Fig 4.3B).   
In contrast, by P19, the levels of Apaf-1 and caspase-3 were markedly reduced (Fig. 
4.3A).  This suggests that the resistance of P19 extracts to cytochrome c was likely due to the 
absence of Apaf-1 and caspase-3. 
We next examined whether the resistance of P13 cerebellar extracts to cytochrome c 
was due to a functional defect in Apaf-1, caspase-9, or caspase-3.  S-100 Cytosolic lysates 
were prepared from mouse embryonic fibroblasts (MEFs) isolated from wildtype mice or 
mice deficient in Apaf-1, caspase-9, or caspase-3, and assessed for their ability to 
complement the defect in P13 cerebellar extracts.  Addition of caspase-9-/- or caspase-3-/- 
MEF extracts (which have no independent ability to cleave DEVD-afc upon the addition of 
cytochrome c) fully complemented the P13 cerebellar extracts and allowed cytochrome c to 
activate caspases, indicating that there was no defect in caspase-9 or caspase-3 in P13 
cerebellar neurons (Fig. 4.3C).  In contrast, Apaf-1-/- MEF extracts failed to complement the 
P13 cerebellar extracts.  These results indicate that while P13 cerebellar extracts maintain 
levels of Apaf-1 protein, this protein is nonfunctional.  Indeed, we found that the simple 
addition of recombinant Apaf-1 protein (human Apaf-1; kind gift of Dr. Xiaodong Wang, UT 
Southwestern) fully restored cytochrome c-mediated caspase activation to P13 cerebellar 
extracts (Fig. 4.3D,E).   
Addition of Apaf-1 protein alone to P19 cerebellar extracts was not sufficient to induce 
activation of caspases upon the addition of cytochrome c (Fig. 4.3D,E), presumably since 
these extracts still lack caspase-3. 
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Together, these data show that cerebellar neurons go though multiple, distinct events in 
which cytochrome c-mediated caspase activation becomes increasingly restricted with 
maturation (Fig. 4.6).  In particular, our data point to a novel, posttranslational mechanism by 
which Apaf-1 activity is inhibited in P13 cerebellar neurons 
 
4. Apaf-1 phosphorylation occurs in P5 but not P13 cerebellar neurons 
The inability of Apaf-1 to function in P13 cerebellar lysates could be due to an inability 
of cytochrome c to bind Apaf-1, or a defect in the recruitment of caspase-9 to Apaf-1.  To 
examine this more closely, either His-tagged cytochrome c protein, or GST tagged CARD 
domain of caspase-9 was incubated with P5 or P13 lysates.  Cytochrome c binding to Apaf-1 
occurs via Apaf-1’s C-terminal WD-40 repeat domain, whereas caspase-9 and Apaf-1 
interact via a CARD/CARD interaction (Fig 4.4A).  The ability of endogenous Apaf-1 to 
bind either His-Cyt c or GST-Casp-9-CARD was then analyzed by Western blot.  While 
cytochrome c appeared to bind Apaf-1 equally in both P5 and P13 lysates, the ability of 
caspase-9 to interact with Apaf-1 was diminished in P13 lysates (Fig. 4.5A).   
Although no role for phosphorylated Apaf-1, nor a specific phsophorylation site on this 
protein has been identified, recent data suggests that Apaf-1 can become phosphorylated in 
BCR-Abl overexpressing cells, or by overexpression of PKA (Deming, Schafer et al. 2004; 
Martin, Allan et al. 2005).  To examine whether phosphorylation of Apaf-1 affects its activity 
in the developing cerebellum, we examined the phosphorylation status of Apaf-1 in P5 and 
P13 lysates.  Due to the large size of Apaf-1 and the difficulty in immunoprecipitating this 
protein, we constructed a GST tagged domain of Apaf-1 deleted for the WD-40 repeat 
region.  This GST-Apaf (aa 1-543) retains the caspase-9 binding CARD domain, as well as 
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the Nucleotide Binding Domain (Fig 4.4B).  Purified Apaf-1 GST (aa 1-543) protein was 
then incubated with either P5 or P13 cerebellar lysate in the presence of [γ-32P]ATP and 
analyzed by autoradiography.  Interestingly, P5, but not P13 was able to phosphorylate GST-
Apaf-1 (aa 1-543) (Fig 4.5B).   Although only correlative, this data suggests that 
phosphorylation of Apaf-1 may be necessary for its activity, and that as cerebellar neurons 
differentiate, phosphorylation of Apaf-1 is lost to ensure a stricter regulation of apoptosis. 
 
D. Discussion  
In this study, we have examined whether differentiating neurons of the CNS acquire an 
increased regulation of the apoptotic pathway.  Indeed, we find that just as postmitotic 
sympathetic neurons are resistant to cytochrome c, differentiating granule neurons develop an 
inability to undergo cytochrome c-mediated apoptosis.  In neurons of the developing 
cerebellum, we identify four distinct stages of apoptotic regulation (Fig 4.6).  1) At an early 
developmental age (P5), apoptosome components are maintained at high levels, Apaf-1 is in 
a phosphorylated state, and cerebellar neurons are completely sensitive to cytochrome c.  2) 
At P10, apoptosome components are still highly expressed, but neurons have a reduced 
sensitivity to cytochrome c that is mediated, in part, by XIAP’s inhibition of caspases.  3)  As 
neurons differentiate and begin to migrate toward the inner granule layer (P13) they lose the 
ability to undergo apoptosis induced by cytochrome c.  Expression of apoptosome 
components are still high, however, Apaf-1 is no longer functional, perhaps due to its 
dephosphorylation.  4) Mature neurons of the cerebellum (P19) are completely resistant to 
cytochrome c and have severely reduced Apaf-1 and caspase-3 levels. 
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We were intrigued to find that the inhibition of cytochrome c-mediated apoptosis in 
cerebellar neurons was a result of posttranslational inactivation of Apaf-1.  Our lab has 
extensively studied the regulation of the apoptotic pathway in postmitotic sympathetic 
neurons as well as cardiomyocytes.   In these cells, cytochrome c-mediated apoptosis is 
inhibited by the coordinated suppression of caspase activation by XIAP and low Apaf-1 
levels.  In mitotic cells and immature sympathetic neurons, Apaf-1 levels are high, 
overwhelming XIAP’s ability to inhibit caspase activation and apoptosis.  In postmitotic 
sympathetic neurons as well as cardiomyoctyes, however, the levels of Apaf-1 are extremely 
low, and XIAP becomes a critical inhibitor of caspase activation and cell death (Fig 1.2), 
(Wright and Deshmukh 2006; Vaughn and Deshmukh 2007).  The data from this study, 
however, suggests that not all postmitotic neurons regulate cytochrome c-mediated caspase 
activation by similar mechanisms.  In CGNs, the transient role that XIAP plays to inhibit 
caspase activation (P10 cerebellum) (Fig. 4.2), occurs ar a stage when Apaf-1 levels are quite 
high.  It is likely that the ability of XIAP to affectively inhibit caspase activation at this stage 
is because Apaf-1 begins to be inactivated by dephosphorylation. 
Interestingly, by P13, cerebellar lysates were unable to be activated by cytochrome c 
even when XIAP activity was inhibited.  Despite this, Apaf-1 levels remain high in P13 
cerebellar neurons.  Our data suggests that cerebellar neurons can regulate apoptosis by a 
posttranslational modification in Apaf-1 that inhibits the ability of Apaf-1 to interact with 
caspase-9.  Although the exact mechanism by which Apaf-1 is inhibited in P13 cerebellum is 
still unclear, the phosphorylation status of Apaf-1 directly correlates with its activity in the 
developing cerebellum. 
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At later ages in the mature cerebellum, the apoptotic pathway becomes further 
restricted by multiple means.  By almost three weeks after birth, the addition of recombinant 
Apaf-1 protein is no longer able to restore activity to these lysates, and levels of Apaf-1 and 
caspase-3 are virtually undetectable (Fig 4.3D,E).  While our lab and others have shown that 
levels of apoptosome components are reduced with neuronal maturation (Yakovlev, Ota et al. 
2001; Donovan and Cotter 2002; Wright, Linhoff et al. 2004), here, we uncover multiple and 
distinct stages by which developing neurons confer resistance to apoptosis.   
These multiple stages of increasing inhibition on the apoptotic pathway could be 
advantageous to ensure the proper developoment of the cerebellum.  During the first 
postnatal week, mitotic neuronal precursors have no need to strictly inhibit the apoptotic 
pathway as they are plentiful and have regenerative potential.  As these neurons begin to 
differentiate, however, they become more cautious about undergoing apoptosis.  
Posttranslational inhibition of Apaf-1 is an efficient mechanism by which neurons can 
quickly restrict the apoptotic pathway, or easily reverse this inhibition in order to remove a 
damaged or misdirected cell.  Once a neuron has matured, it downregulates the expression of 
multiple apoptotic components.  It’s abilty to strictly inhibit apoptosis is crucial at this age, as 
these neurons have now established elaborate neural connections, and cannot be readily 
replaced. 
 
E. Materials and Methods 
Reagents 
All reagents were purchased from Sigma (St. Louis, MO) or Fisher Scientific (Pittsburgh, 
PA) unless otherwise stated.  [γ-32P]ATP was purchased from Perkin Elmer.  Recombinant 
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SMAC protein was purified from bacteria as described previously (Potts 2003).   Apaf-1 
protein was a kind gift of Dr. Xiaodong Wang (UT Southwestern, Dallas).  ICR outbreed 
mice (Harlan Sprague Dawley) were used for all experiments except those involving Apaf-1, 
caspase-3, XIAP, and caspase-9 deficient cells.  For these the background is C57BL/6.  Apaf-
1 deficient mice were generated by Dr.Joachim Herz (UT Southwestern) and were kindly 
provided by the laboratory of Dr. Susan Ackerman (Jackson Laboratories). 
 
Preparation of Cytosolic Extracts 
For extracts from whole cerebellum, cerebellum from various aged ICR mice were dissected, 
minced, trypsinized, and dissociated.  Cells were passed through a cell filter, washed in PBS 
and resuspended in hypotonic lysis buffer (10 mM Hepes, pH 7.5, 10 mM KCl, 0.5 mM 
EDTA, 1 mM EGTA, 1 mM MgCl2, 1 mM DTT) and rotated at 4 degrees for 20 minutes, 
followed by passage through a p200 pipette tip to lyse cells.  S100 lysates were prepared by 
centrifugation at 16,000 x g to remove nuclei and heavy membrane fractions.  The 
supernatant was then centrifuged for 30 min at 100,000 x g to remove the light membrane 
fraction.  For cultured cells, cells were washed 3 x in PBS, and cells collected by scraping.  
The cell pellet was lysed as above only passaged through a 25-gauge needle.  Centrifugation 
was done as described above, and the resulting supernate was used for caspase activation 
assays.   
 In vitro caspase activation assays were performed by incubating equal protein (50 ug) 
of cytosolic lysate with 1mM dATP and 10 uM cytochrome c in oligimerization buffer (25 
mM HEPES, pH 7.5, 50 mM NaCl, 10 mM KCl, 1.5 mM MgCl2, 10% glycerol, 1mM DTT) 
for 15 minutes at 37 degrees.  The caspase substrate, DEVD-afc was then added at a 
 121
concentration of 50 uM to bring the total volume up to 100 ul.  Fluorescent intensity was 
measured over time on a Fluoroskan fluorescent plate reader.    
 
Granule Neuron Cultures 
Primary cultures of Cerebellar Granule Neurons were obtained as described previously 
(Miller and Johnson 1996).  Briefly, postnatal day 5 (P5) cerebellar were dissected triturated, 
and plated into 0.1 mg/ml poly-L-lysine coated 60 mm dishes containin K25 + S medium at 
density of four million cells per plate.  After 24 hours, neurons were treated with 100 nM 
AraC to reduce the accumulation of non-neuronal cells. These cultures were maintained for  
1 day or 12 days in culture before preparation of cytosolic extracts.   
 
Western Blot Analysis  
To assess the endogenous levels of proteins throughout cerebellum development, Western 
analysis was performed on untreated cerebellar.  To assess caspase processing, cytochrome c 
alone or along with SMAC or Apaf-1 protein was incubated with lysates.  The following 
antibodies were used; anti-Apaf-1 (13F11; Alexis Biochemicals), anti-LDH (Rockland), anti-
active caspase-3 (Cell Signaling), anti-active caspase-9 (Cell signaling).  Anti-rabbit/rat 
HRP-conjugated secondary antibodies were purchased from Pierce Chemical Co.  Western 
blots were developed with ECL-plus reagents (Amersham Biosciences). 
 
Phosphorylation Assay 
GST-Apaf-1 (aa 1-543) attached to glutathione sepharose was incubated with 0.5 mg 
cytosolic lysate from either P5 or P13 cerebellum in the presence of 15 mM MgCl2, 10 mM 
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cold ATP and 0.01 mCi  [γ-32P]ATP in a volume of 100 ul for one hour at 30°C.  Beads were 
washed 5 x in RIPA + 500 mM NaCl.  Beads were then boiled in SDS sample buffer, and 
supernate was run on an 8% SDS PAGE gel and analyzed by scanning onto the Typoon 
phosphoimager.   
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F. Figures and Legends 
 
 
 
Figure 4.1. Cytochrome c is sufficient to induce caspase activation in P5 (mitotic), but not in 
P13 (postmitotic) cerebellar extracts.  A) S100 extracts were made from the cerebellum of 
P5, P13, or P19 widltype mice.  The ability of activated caspases to cleave DEVD-afc was 
measured over time following the addition of 10 uM bovine cytochrome c.  B) Lysates 
activated in (A) were analyzed by Western analysis with antibodies detecting activated 
caspase-9, activated caspase-3, and LDH as a loading control.  C) Cerebellar granule neurons 
were cultured from P4 mice for either 24 hours (P5 equivalent), or for nine days (P13 
equivalent).  Neurons were then collected and made into S100 extract.  The ability of these 
extracts to activate caspases was measured by DEVD-afc cleavage after the addition of 10 
uM cytochrome c.  
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Figure 4.2. The inability of cytochrome c to induce apoptosis in P13 cerebellar extracts is 
not due to regulation by IAPs.  A) Cerebellar extracts from P5 and P13 mice were examined 
for their ability to activate caspases (cleave DEVD-afc) in the presence of cytochrome c (10 
uM) and the IAP inhibitor, SMAC (4 mg/ml).  B) Lysates from (A) were analyzed or 
Caspase-9 and Caspase-3 cleavage by Western blot.  LDH serves as a loading control.  C)  
Extracts were made from the cerebellum of either XIAP-/- mice, or their wildtype littermates 
at P10.  Their ability to activate caspases was measured following addition of cytochrome c.     
 126
P5 P13 P19 P5 P13 P19
+ Smac
A B
3500
3000
2500
2000
1500
1000
500
0
0 20 40 60 80
Time (min)
P5 + Cyt c
P13 + Cyt c
P19 + Cyt c
C
as
pa
se
 A
ct
iv
at
io
n 
(D
EV
D
-a
fc
 C
le
av
ag
e)
P5 + Cyt c + Smac
P13 + Cyt c + Smac
P19 + Cyt c + Smac
1000
0
200
400
600
800
1200
1400
1600
0 20 40 60 80
Time (min)
P10 XIAP+/++ Cyt c
P10 XIAP-/- + Cyt c
C
as
pa
se
 A
ct
iv
at
io
n 
(D
EV
D
-a
fc
 C
le
av
ag
e)
C
Cleaved Caspase-9
Cleaved Caspase-3
LDH
Figure 4.2
127
  
 
 
Figure 4.3.  P13 Cerebellar Neurons Exhibit a Specific Defect in Apaf-1 Activity, Despite 
maintaining High Levels of Apaf-1 Protein.  A)  Cerebellar extracts were made from P5, P13 
and P19 cerebellum, and the levels of the apoptosome components were examined by 
Western analysis.  LDH is shown as a loading control.  B)  Cerebellar extracts from P5 and 
P13 were mixed, and the ability of cytochrome c to activate caspases was measured by 
caspase activation assay. C) S100 cytosolic extracts were made from cultures of wildtype, 
caspase-3-/-, caspase-9-/- and Apaf-/- MEFs.  The ability of these extracts to complement the 
defect in P13 cerebellar extracts was examined by incubating MEF lysate (50 ug) with P13 
lysate (50ug) in the presence of cytochrome c.  Caspase activation was measured as 
described for the caspase activation assay.  D)  Recombinant Apaf-1 (20 nM) was incubated 
with P13 or P19 cerebellar lysate in the presence of cytochrome c, followed by quantitation 
of caspase activation.  E)  Lysates from (C) were analyzed for caspase activation by Western 
blot.  
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Figure 4.4  Domain structure of Apaf-1.  A) Apaf-1 contains an N-terminal Caspase 
Recruitment Domain (CARD), a Nucleotide Binding Domain (NBD), and 13 C-terminal 
WD-40 repeats.  B) Apaf-1 lacking the WD-40 repeats was fused to a GST tag to make GST-
Apaf-1 (aa 1-543). 
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Figure 4.5  Apaf-1 phosphorylation occurs in P5 but not P13 cerebellar neurons. A) The 
ability of His-Cyt c or GST-Casp-9-CARD was assed for its ability to bind Apaf-1 in P5 and 
P13 lysates.  Recombinant protein was incubated with cerebellar extracts, followed by 
removal of His-Cyt c and GST-Casp-9-CARD with nickel beads, or Glutathione sepharose, 
respectively.  Beads were washed in 500 mM NaCl, and binding partners examined by 
Western analysis. B)  Recombinant protein of GST-Apaf-1 (aa 1-543) was incubated with 
lysates in the presence of [γ-32P]-ATP.  GST-Apaf-1 (aa 1-543) was removed from the 
lysates with Glutathione Sepharose, and phosphorylation of GST-Apaf-1 (aa 1-543) analyzed 
by autoradiography. 
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Figure 4.6  In neurons of the developing cerebellum, we identify four distinct stages of 
apoptotic regulation. 1) At an early developmental age (P5), apoptosome components are 
maintained at a high level, Apaf-1 is in a phosphorylated state, and cerebellar neurons are 
completely sensitive to cytochrome c.  2) At P10, apoptosome components are still highly 
expressed, but neurons have a reduced sensitivity to cytochrome c that is mediated in part by 
XIAP.  3)  As neurons differentiate and begin to migrate toward the inner granule layer (P13) 
they lose the ability to undergo apoptosis induced by cytochrome c.  Expression of 
apoptosome components are still high, however, Apaf-1 is no longer functional, perhaps due 
to a reduction in its phosphorylation.  4)  Mature neurons of the cerebellum (P19) are 
completely resistant to cytochrome c and have severely reduced Apaf-1 and caspase-3 levels. 
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V. CHAPTER FIVE: 
Discussion 
A.  Summary of Findings 
 
 Unlike normal mitotic cells which are easily replaceable, postmitotic neurons have 
limited regenerative potential and must last the lifetime of the organism.  The work from this 
dissertation provides evidence for two main hypotheses about neuronal apoptosis.  First, it 
proposes that unlike normal mitotic cells, neurons have developed multiple mechanisms by 
which they strictly regulate the apoptotic pathway to ensure their longterm survival.   In 
support of this hypothesis, I have identified two novel mechanisms (described in Chapter 
Three and Four) by which neurons inhibit the apoptotic pathway.  Second, this dissertation 
proposes that the mechanisms by which neurons strictly inhibit the apoptotic pathway are 
reversible in order to cell death in appropriate situations.  In Chapter Two and Three, I 
describe novel mechanisms by which blocks on the apoptotic pathway are removed in 
response to DNA damage and developmental and pathological situations of increasing ROS, 
respectively.  In addition, work from this dissertation uncovers a specific mechanism utilized 
by neurons and cancer cells to restrict apoptosis.  This discovery opens the possibility that the 
multiple mechanisms present in neurons to restrict apoptosis and ensure their longterm 
survival may also be used by cancer cells for the evasion of apoptosis.  Chapter Three 
addresses similarities between how neurons and cancer cells regulate apoptosis via the redox 
state of cytochrome c.   
 
CHAPTER TWO:  Essential Postmitochondrial Role of p53 Uncovered in DNA Damage-
Induced Apoptosis in Neurons 
Summary of Findings 
 
1.  XIAP is degraded following NGF deprivation, but remains stable after DNA damage  
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2. Unlike NGF deprivation, etoposide-induced death requires translation to overcome 
XIAP 
3. Apaf-1 is markedly induced in etoposide treated sympathetic neurons 
4. p53 deficient neurons are unable to overcome XIAP’s inhibition of caspases in 
response to DNA damage 
5.  p53 induces the expression of Apaf-1 induction in response to DNA damage; an 
event necessary to overcome XIAP’s inhibition of caspases and promote apoptosis in 
neurons 
 
 Previous work from this lab and others has shown that while cytosolic cytochrome c 
is sufficient to induce apoptosis in mitotic cells, it is unable to do so in postmitotic 
sympathetic neurons (Deshmukh 1998; Neame, Rubin et al. 1998).  Work that followed, 
demonstrated that the resistance of sympathetic neurons to cytosolic cytochrome c was due to 
the inhibition of caspase activation by XIAP (Potts, Singh et al. 2003).  This finding was: 1) 
unique because a function for endogenous XIAP had not been desmonstrated for other cell 
types (Harlin, Reffey et al. 2001), and 2) curious because cytochrome c was found to be 
capable of inducing apoptosis in mitotic cells which express ample amounts of XIAP.   
The removal of XIAP is required for cytosolic cytochrome c to induce apoptosis in 
neurons.  Therefore, we wanted to examine the mechanism by which XIAP is overcome in 
pathological situations of DNA damage-induced apoptosis.  Interestingly, we found that, 
unlike NGF deprivation which inhibits XIAP by selectively degrading it, DNA damage did 
not alter the levels of XIAP.  Instead, XIAP was overcome by a p53-mediated upregulation 
of Apaf-1.  These data are significant because they demonstrate that the mechanisms utilized 
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by neurons to overcome XIAP to permit cytochrome c-mediated apoptosis are stimulus 
specific.  These results are also the first to identify a postmitochondrial mechanism by which 
p53 can regulate the apoptotic pathway in mammalian cells (discussed in more detail in 
Chapter Two).   It is likely that other postmitotic cells which exhibit increased regulation of 
apoptosis due to XIAP activity (e.g. Cardiomyocytes; (Potts, Vaughn et al. 2005)) would also 
require p53-mediated induction of Apaf-1 in order to undergo apoptosis by DNA damage.  
 
CHAPTER THREE: Glucose Metabolism Inhibits Apoptosis in Neurons and Cancer Cells 
by Redox Inactivation of Cytochrome c 
Summary of Findings 
1. Endogenous cytochrome c release is capable of inducing apoptosis in mitotic 
fibroblasts, but incapable of inducing apoptosis in sympathetic neurons. 
 
2.  Endogenous cytochrome c release is incapable of inducing apoptosis even in XIAP 
deficient sympathetic neurons.   
 
3.  NGF deprivation makes endogenous cytochrome c capable of inducing apoptosis in 
sympathetic neurons 
 
4.  An increase in the oxidative environment enables cytochrome c to induce apoptosis 
cells, whereas a reduced cellular environment inhibits the proapoptotic activity of 
cytochrome c.  Whereas cytochrome c is active in an oxidized state, reduced 
cytochrome is less able to induce apoptosis. 
 
5.  Healthy neurons maintain a highly reduced environment via glucose metabolism 
through the pentose phosphate pathway and production of GSH. 
 
6.  Inhibition of GSH synthesis through the pentose phosphate pathway sensitizes 
neurons to cytochrome c. 
 
7.  NGF deprivation creates a cellular environment capable of oxidizing cytochrome c, 
thereby permitting apoptosis.  
 
8.  Like neurons, cancer cells have elevated GSH and are resistant to cytochrome c. 
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9. Glucose deprivation or inhibition of the pentose phosphate pathway increases ROS 
and sensitizes cancer cells to cytochrome c induced apoptosis. 
 
Because postmitotic neurons have an increased need to regulate apoptosis, it is likely 
that multiple mechanisms exist in neurons that would inhibit apoptosis.  In Chapter Three, I 
identified a novel mechanism by which neurons inhibit the apoptotic pathway.  In brief, I 
report that the ability of cytochrome c to activate the apoptotic pathway is dependent on its 
redox status.  The endogenous release of cytochrome c is not capable of inducing apoptosis 
in neurons because it is held in a reduced and inactive state. 
It is important to note that this observation could not have been made using the same 
techniques which identified XIAP as an inhibitor of apoptosis in sympathetic neurons.  In 
those experiments, an excess amount of exogenous cytochrome c protein (which is mostly 
oxidized, and therefore capable of activating apoptosis in the absence of XIAP) was 
introduced by microinjection into the cytosol of cells.  Only by directly inducing endogenous 
release of cytochrome c from mitochondria in intact cells (via tBid) did it become apparent 
that even in the absence of XIAP, cytochrome c was still incapable of promoting apoptosis in 
neurons. 
Here we show that in healthy neurons, glucose flux through the pentose phosphate 
pathway produces reduced glutathione which helps to maintain cytochrome c in a reduced 
and inactive state.  Just as we see with XIAP inhibition in Chapter Two, the redox 
inactivation of cytochrome c in neurons is reversible.  During apoptosis induced by NGF 
deprivation or DNA damage, glycolytic pathways are compromised resulting in an increase 
in ROS.  As cytochrome c is released into the cytosol, it becomes oxidized and apoptotically 
active.  
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This work is significant because it provides a direct link between cellular metabolism, 
the production of ROS, and the activation of key players in the apoptotic pathway.  It also 1) 
proposes that cancer cells and neurons have adapted similar methods by which they can 
evade apoptosis, and 2) provides a mechanism by which the Warburg effect (and enhanced 
use of glycolysis in cancer cells) could mediate protection or cancer cells from apoptosis.  
 
CHAPTER FOUR: Age-Dependent Changes in the Regulation of Apoptosis in Neurons 
 
Summary of findings 
 
1. Cytochrome c is sufficient to induce caspase activation in P5 (mitotic), but not in P13 
(postmitotic) cerebellar neurons. 
 
2.  The inability of cytochrome c to induce apoptosis in p13 cerebellar neurons is not 
due to inhibition of caspases by IAPs. 
 
3.  Differentiating cerebellar neurons exhibit a specific defect in Apaf-1 activity, despite 
maintaining high levels of Apaf-1 protein. 
 
4.  P13 neurons exhibit a defect in the ability of Apaf-1 to bind to caspase-9. 
 
5.  P5 and P13 neurons exhibit differential phosphorylation of Apaf-1. 
 
6.  With subsequent maturation (P19), cerebellar neurons exhibit a marked reduction in 
expression of apoptosome components. 
 
While our lab and others have extensively studied the mechanisms by which 
sympathetic neurons regulate the apoptotic pathway in response to cytochrome c, whether 
this is a phenomenon shared by other neurons, particularly those of the CNS, is less known.  
In Chapter Four, I have used cell-free assays to determine that, like sympathetic neurons, 
granule neurons in the early stages of cerebellar development remain sensitive to cytochrome 
c, but become completely resistant as the cerebellum continues to develop and mature.  
While a reduction in Apaf-1 levels contributes to the resistance of sympathetic neurons to 
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cytochrome c, cerebellar neurons lose Apaf-1 activity despite maintaining high levels of 
Apaf-1 protein.  While this data is still preliminary, we find that the phosphorylation status of 
Apaf-1 positively correlates to the sensitivity of neuronal extracts to cytochrome c.   This 
work is significant as it is the first to identify a posttranslational regulation of Apaf-1 in a 
physiological context such as cerebellar development.   
 
B. Discussion 
Although all three chapters in this dissertation address novel mechanisms by which the 
apoptotic pathway is inhibited in neurons, Chapter Three specifically examines similarities 
between the regulation of apoptosis in neurons and cancer cells.  In this section, I will discuss 
the possibility that the novel mechanisms regulating apoptosis described in both Chapters 
Two and Four may also be adapted by cancer cells to evade apoptosis.  Finally, I will 
examine the implications that these findings may have on our understanding of how neuronal 
loss contributes to aging and neurodegenerative disease. 
 
1. Cancer Cells and Neurons: a fight for survival 
Postmitotic cell such as neurons have adapted to strictly regulate the apoptotic pathway 
to ensure their longterm survival.  However, easily replaceable mitotic cells tend to lack these 
brakes, and more readily undergo apoptosis in the event of stress.  A heightened 
susceptibility to apoptosis is especially important for mitotic cells to ensure that damaged 
DNA is not passed down to daughter cells.  Unfortunately, rare events that inhibit the 
apoptotic pathway can cause a normal cell to proliferate through these checks, leading to 
malignancy.  Therefore, despite the morphological and functional differences between 
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postmitotic neurons and cancer cells, a characteristic common to both cell types is their 
increased ability to inhibit apoptosis. 
One theory that has developed from this dissertation proposes that some of the 
mechanisms by which neurons strictly regulate apoptosis could be the same ones adopted by 
cancer cells to evade apoptosis.  In support of this, Chapter Three demonstrates that both 
neurons and cancer cells restrict apoptosis by maintaining released endogenous cytochrome c 
in a reduced and thus apoptotically inactive state.   Although this is the only chapter which 
examines such similarities between neurons and cancer cells, I would hypothesize that cancer 
cells may have also commandeered the methods described in Chapters Two and Four used by 
neurons to inhibit apoptosis.  I discuss evidence for these possibilities, and their implications 
below.  
 
Do both cancer cells and neurons regulate apoptosis via XIAP activity? 
In postmitotic cells such as sympathetic neurons and cardiomyocytes, XIAP plays a 
crucial role in mediating sensitivity of cells to cytochrome c (Potts, Singh et al. 2003; Potts, 
Vaughn et al. 2005).  Unlike normal mitotic cells where cytochrome c is capable of 
activating caspases even in the presence of XIAP, postmitotic neurons and cardiomyocytes 
are resistant to cytochrome c unless XIAP is removed.  Interestingly, many cancers may have 
also adapted to use IAPs in the regulation of apoptosis.  Levels of ML-IAP are overexpressed 
in the majority of melanomas, and other IAPs, including XIAP, are upregulated in nonsmall 
cell lung cancer, prostate cancer, and a variety of lymphomas and leukemias (Vucic, 
Stennicke et al. 2000; Hofmann, Simm et al. 2002; Altieri 2004; Nachmias, Ashhab et al. 
2004; Zangemeister-Wittke and Simon 2004; Wright and Duckett 2005).  Consistent with the 
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expectation that increased expression of IAPs inhibit apoptosis in cancer cells, small peptide 
mimics of the endogenous IAP inhibitor, SMAC, are able to sensitize a variety of tumor 
derived cell lines and mouse models of tumors to apoptosis (Fulda, Wick et al. 2002; Li, 
Thomas et al. 2004; Schimmer, Welsh et al. 2004; Bockbrader, Tan et al. 2005).  If IAPs are 
indeed important for cancer cell survival, one prediction is that animals deficient in XIAPs 
may have a reduced susceptibility to certain types of tumors. 
 
Do both cancer cells and neurons regulate cytochrome c-mediated apoptosis by modulation 
of Apaf-1 expression? 
Although the inhibition of XIAP activity is only required for postmitotic cells, and not 
normal mitotic cells, to undergo cytochrome c-mediated apoptosis, there is no difference in 
the levels of XIAP between these two cell types.  Instead, levels of the proapoptotic protein, 
Apaf-1 are dramatically reduced in postmitotic cells as compared to normal mitotic cells 
(Wright, Linhoff et al. 2004; Potts, Vaughn et al. 2005).  It is this low level of Apaf-1 in 
neurons and cardiomyocytes which allows the XIAP brake to be engaged, making these cells 
insensitive to cytochrome c.   Interestingly, certain cancer cells have also hijacked this 
technique of inhibiting apoptosis, as a variety of cell lines including melanoma and leukemia 
have decreased expression of Apaf-1, and thus a higher threshold for apoptosis (Jia, 
Srinivasula et al. 2001; Soengas, Capodieci et al. 2001).     
 
Does p53 regulate apoptosis downstream of mitochondria in neurons and cancer cells? 
In Chapter Two of this dissertation I show that in order for neurons to overcome XIAP 
inhibition of caspases and undergo apoptosis following DNA damage, they must re-express 
 144
sufficient levels of Apaf-1.  From these studies in neurons, one could predict that cancer cells 
exhibiting reduced Apaf-1 levels or increased expression of XIAP may also upregulate Apaf-
1 to undergo apoptosis mediated by DNA damage.  In neurons, we show that the 
transcription factor p53 mediates the increase in Apaf-1 in response to DNA damage.  While 
p53 has a well known role in apoptosis at the mitochondria (e.g. upregulation of apoptotic 
Bcl-2 proteins), our results could provide an additional explanation to why cancers deficient 
in p53 are often resistant to DNA damaging therapeutics.  It would be interesting to examine 
whether cancer cells with intact p53 respond better than p53 deficient tumors to DNA 
damaging therapeutics in part due to their ability to re-express Apaf-1.  In addition, this 
would suggest that in order to treat cancers carrying mutations in p53 as well as defects in 
Apaf-1 expression, therapeutics must not only induce the release of cytochrome c from the 
mitochondria, but also target XIAP activity. 
 
Do both neurons and cancer cells regulate Apaf-1 postranslationally to inhibit apoptosis? 
A reduction in Apaf-1 levels in sympathetic neurons and cardiomyocytes engages 
XIAP activity and protects these cells from cytochrome c-mediated apoptosis.  However, as 
described in Chapter Four of this dissertation, postmitotic neurons at mid stages in cerebellar 
development regulate apoptosis not by modulating levels of Apaf-1, but by redering it 
inactive posttranslationally.  Interestingly, certain cancers seem regulate the apoptosome in a 
similar manner.  Work from Dr. Doug Green’s laboratory shows that a variety of ovarian 
cancer cell lines are defective for Apaf-1 activity despite adequate expression of this protein 
(Wolf, Schuler et al. 2001).  Consistent with our observations in the developing cerebellum, 
this inactivation does not seem to be a result of a dominant Apaf-1 inhibitor, or altered 
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expression of Apaf-1 isoforms.  Future experiments would need to be done to determine 
whether the posttranslational inhibition of Apaf-1 is accomplished by similar means in the 
developing cerebellum as in ovarian tumors.   
Although correlative, our data in the developing cerebellum suggests that 
phosphorylation could be the posttranslational motif regulating the apoptotic activity of 
Apaf-1.  Work in Dr. Sally Kornbluth’s lab at Duke have shown that phosphorylation of 
Apaf-1 occurs in cells overexpressing the oncogene, BCR-Abl (Deming, Schafer et al. 2004), 
To date, however, the sites of Apaf-1 phosphorylation have not been determined.  It would be 
interesting to ask in the future whether phosphorylation of Apaf-1 is a key regulator of Apaf-
1 function in cerebellar neurons as well as cancer cells.   
 
2. Relevance to Neurodegeneration and Aging 
   This dissertation examines three mechanisms which neurons have evolved to inhibit 
the apoptotic pathway.  Yet, despite these multiple protective mechanisms, neuronal cell 
death is a key feature of many neurodegenerative diseases as well as aging.  We find that the 
mechanisms utilized by neurons to inhibit apoptosis are reversible.  Therefore, I would 
propose that that the failure to acquire these molecular events, or their aberrant disruption 
could be features of neurodegenerative disease and aging, and would sensitize neurons to 
stress and eventual cell death.  
  
Is deregulation of XIAP activity or Apaf-1 expression relevant to neurodegeneration and 
aging? 
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 Postmitotic neurons are unable to undergo cytochrome c-mediated cell death due to a 
brake on caspases by XIAP.  Chapter Two shows that this inhibition of caspases is reversible, 
being overcome in developmental apoptosis by XIAP degradation, or in phathological 
apoptosis by a p53-mediated increase in Apaf-1.  With this information, we could predict that 
XIAP activity would be negatively affected in the context of neurodegenerative disorders.  In 
support of this, studies have shown that in transgenic mouse models of ALS, XIAP levels are 
decreased in contrast with wildtype littermates.  We could also speculate that a reduction of 
XIAP or increase in Apaf-1 may be a risk factor for the development of neurodegenerative 
disorders.  Yolanda Huang in our lab is in the process of examining this question using a 
mouse model of ALS, as well as by examining DNA from  human ALS patients to look for 
mutations in XIAP. 
In addition to the disregulation of XIAP, an inability to inhibit expression of Apaf-1 in 
adult neurons could be a hallmark of cell death in neuronal disease, be it cause or effect.  For 
example, in response to traumatic brain injury, Apaf-1 is upregulated in mice (Yakovlev, Ota 
et al. 2001).  In Chapter Two we show that p53 is required for the induced expression of 
Apaf-1 in response to DNA damage by etoposide.  Interestingly, an induction of p53 activity 
has been reported in numerous neurodegenerative disorders including in Alzheimer’s 
Disease, Parkinson’s Disease, and ischemic injury.  This would suggest that inhibition of p53 
may be a viable target to reduce apoptosis in aging and neurodegeneration (Culmsee and 
Mattson 2005).  Although it is clear that disruption of Apaf-1 or inhibition of XIAP activity 
can sensitize neurons to apoptosis, it is not clear whether disregulation of these proteins is a 
cause or an affect of ailments such as neurodegeneration.  It would be interesting to ask 
whether patients susceptible to neurodegenerative disease inactivate XIAP,or fail to 
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downregulate Apaf-1 during development, thus sensitizing them to cellular stress that 
accumulates with age. 
 
Is cytochrome c activation via ROS important for neurodegeneration and aging?   
 We have shown that in healthy postmitotic neurons, a reduced cellular environment 
holds the proapoptotic activity of cytochrome c in check.  Such a checkpoint would be 
critical for a postmitotic cell in particular, in the event of accidental release of cytochrome 
into the cytosol.  For example, in a mitotic cell, if mitochondria become damaged and leak 
cytochrome c, it may be more efficient for the organism to remove this cell by apoptosis than 
to repair the damage.  However, for an irreplaceable neuron, the risk of losing this neuron 
most likely outweighs the price of repairing it.  
Despite the necessity for neurons to strictly inhibit the apoptotic pathway, our work 
shows that the inactivation of cytochrome c can be reversed by a disruption in the redox 
balance of the cell.  Interestingly, this balance is disrupted in a myriad of neurodegenerative 
diseases and with age.  Many studies, including the free radical hypothesis of aging (Harman 
1992), suggest that an imbalance between generation of oxygen radicals and antioxidants 
may be involved the pathogenesis of many neurodegenerative diseases (Eckert, Keil et al. 
2003; Eckert, Marques et al. 2003).  An increase in ROS and oxidative damage have been 
described as a very early event in patients with Alzhemier’s disease and Parkinson’s Disease 
(Castellani, Hirai et al. 2002; Eckert, Keil et al. 2003; Eckert, Marques et al. 2003; Schubert 
2005; Nunomura, Castellani et al. 2006).  Despite this multitude of research, it is still 
unknown whether oxidative damage constitutes a cause or effect of the disease.  Data from 
this thesis suggests, that even if the cellular damage caused by ROS accumulation is not great 
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enough to cause death of the cell on its own, ROS can directly activate a key player (i.e. 
cytochrome c) in the apoptotic pathway, making neurons more susceptible to apoptosis in the 
event of any mitochondrial damage resulting in release of cytochrome c into the cytosol.  
Not only does my work implicate ROS as a regulator of cytochrome c activity and 
apoptosis, but it identifies glucose metabolism as an important factor in maintaining redox 
homeostasis and thus restriction of apoptosis in neurons.  From this we could predict that 
disruption of glucose metabolism would also sensitize neurons to apoptosis by cytochrome c.  
Indeed, a general disruption in glucose metabolism such as glucose deprivation can lead to 
accumulation of ROS (Gibson 2002).  Such a disruption in glucose metabolism has been 
implicated in the pathology of neurodegenerative disorders such as Alzheimer’s disease 
(Gibson 2002; Schubert 2005).   For example, a reduction in glucose metabolism can predict 
cognitive decline in adults, which can often lead to the progression of Alzheimer’s Disease 
(Small, Ercoli et al. 2000; Arnaiz, Jelic et al. 2001; de Leon, Convit et al. 2001; De Santi, de 
Leon et al. 2001).  Whether such abnormalities in glucose regulation and ROS accumulation 
sensitize neurons to cytochrome c-induced apoptosis in patients or mouse models of 
neurodegeneration and aging remain to be examined.   
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VI.  APPENDICES 
 
A. APPENDIX A 
Role of Apaf-1 in Neurite Outgrowth 
With the completion of the human genome project, it was discovered that our DNA 
encodes far fewer genes than had previously been anticipated, suggesting that individual 
proteins may have multiple functions within a cell.  The different functions of a particular 
protein could depend on its location, either within a certain cell type or localization within 
the cell itself.  Alternatively, temporal or even expression level differences of a protein could 
dictate its distinct functions.  For example, only a decade ago was it discovered that 
cytochrome c, known classically for its role in the electron transport chain, can also initiate 
apoptosis depending upon its localization within the cell.  In addition, some proteins 
originally thought to be involved only in the cell cycle, take on cell cycle independent roles 
in postmitotic neurons.  Both Pin1 and the Anaphase Promoting Complex (APC) are cell 
cycle genes recently implicated in axonal patterning and outgrowth, and cell death, 
respectively, in postmitotic neurons (Konishi, Stegmuller et al. 2004; Becker and Bonni 
2006).   
Interestingly, components of the apoptotic pathway are constituitively expressed in 
cells, despite the fact that the cell (i.e. neurons) may never undergo apoptosis.  Therefore, it 
is conceivable that cells may utilize some of these components for other cellular tasks.  Some 
of my preliminary findings suggest that Apaf-1 may have a function in neurite extension in 
addition to its well established role in the apoptotic pathway.  
 When sympathetic neurons from Apaf-1 deficient mice are cultured in vitro, their 
ability grow axonal projections seems retarded in comparison with their wildtype littermates.  
To examine this more closely, neuronal explants of either wildtype or Apaf-1-/- neurons were 
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cultured in NGF containing media, followed by quantitation of neurite outgrowth.  While 
wildtype sympathetic neurons had an average axonal length of 182 um by 16 hrs,  Apaf-1-/- 
neurons showed an average projection length of 113 um (Fig A1).   Although preliminary, 
this data suggests that in addition to its crucial role in the apoptotic pathway in sympathetic 
neurons, Apaf-1 may also function to promote neurite outgrowth.    
Apaf-1 is a very large (130 kD) multidomain protein that consists of two protein 
interaction domains (a CARD and WD-40 domain) as well as a nucleotide binding domain.  
Cytochrome c and caspase-9 both interact with Apaf-1 to form the apoptosome during 
apoptosis, therefore it is possible that this same complex could be necessary for neurite 
outgrowth.  Alternatively, Apaf-1 could interact with unknown partners to induce axon 
growth.  To address the first hypothesis, the lab plans to ask whether neurons isolated from 
the caspase-9 deficient mice exhibit a similar defect in axon extension.  If the second 
hypothesis is correct, Apaf-1 may be expected to bind to alternative partners in the cytosol of 
an extending neurite.     
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Figures and Legends 
 
 
 
 
Figure A.  Apaf-1 deficient neurons have a defect in neurite extension.  Sympathetic neurons 
were cultured from Apaf-1-/- mice or their wildtype littermates.  Before plating, ganglia were 
incompletely triturated.  Populations of neurons containing roughly equal numbers were 
photographed 16 hrs after plating.  Neurite length was measured and represented as an 
average lenth after 16 hrs of plating in NGF.    
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B. APPENDIX B 
Role of Cytochrome c Degradation in Neuronal Apoptosis 
 Data in the body of this dissertation introduce three novel ways in by which neurons 
tightly regulate the apoptotic pathway in order to ensure their longterm survival.  In Chapter 
Three in particular, I describe how the apoptotic activity of cytochrome c itself can be 
modified by its redox activity.   In this section, which consists of work not yet included in a 
publication or in the main body of this thesis, I describe an additional mode of regulation of 
the apoptotic pathway in neurons at the point of cytochrome c. 
 In healthy cells, including potmitotic neurons, cytochrome c is localized to the 
mitochondria where it participates in cellular respiration through the electron transport chain.  
However, in mitotic cells, once cytochrome c is released into the cytosol, it accumulates, 
interacts with Apaf-1, inducing its oligimerization, formation of the apoptosome and 
subsequent caspase activation.  In postmitotic sympathetic neurons, the cytochrome c that is 
released from the mitochondria is subjected to rapid degradation which can be visualized if 
the subsequent steps of caspase activation are blocked.  By immunofluorescence, the 
cytochrome c staining pattern goes from a punctate mitochondrial localization in NGF-
maintained neurons to being virtually undetectable when cytochrome c is released from the 
mitochondria (Fig B1).  Not only does this occur in response to cytochrome c release induced 
by tbid, but also occurs after cytochrome c release with NGF deprivation, or even etoposide 
(Fig. B1; data not shown).  This degradation of cytochrome c is mediated by the proteasome, 
as inhibition of the 26S subunit of the proteasome with lactacystin inhibits the degradation as 
shown both by Western analysis and immunofluorescence (Fig B2).   
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 The experiments described in Chapter Three of this dissertation show that the direct 
release of cytochrome c from the mitochondria of sympathetic neurons does not induce 
apoptosis even if XIAP is first removed (Fig 3.1).  However, when cytochrome c release 
occurs in the context of NGF deprivation, cytochrome c is made sufficient to induce 
apoptosis via its oxidation.  It is also possible, however, that the degradation of cytochrome 
in the cytosol could in part explain the inability of released cytochrome c to initiate 
apoptosis.  To address this, cultures of XIAP deficient sympathetic neurons were treated with 
lactacystin or MG132 to inhibit the proteasome, followed by injection of tBid-GFP DNA.  
While untreated neurons did not undergo apoptosis in response to tBid, those treated with 
proteasome inhibitor died by rapid and complete apoptosis (Fig B3).  Although these data are 
preliminary, they suggest that;  1)  neurons possess a unique ability to target cytochrome c 
for degradation once it is in the cytosol, and 2) that the degradation of cytosolic cytochrome c 
may be a protective mechanism to inhibit apoptosis in postmitotic neurons.   
As seen in Chapter Three of this thesis, cancer cells can also adapt mechanisms similar 
to those used by neurons to avoid the induction of apoptosis.  While there is no concrete 
evidence that cancer cells inhibit the apoptotic pathway by degrading cytosolic cytochrome c, 
it is interesting to note that the prostate cancer cell line, DU145, have been found to rapidly 
degrade cytochrome c once it is released from the mitochondria (Dr. Yuri Lazebnik, personal 
communication).   
In the future, the lab hopes to identify the ubiquitin E3 ligase that targets cytochrome c 
for proteasome-mediated degradation in sympathetic neurons.  To address this, we plan to; 1) 
use immunoprecipitation experiments followed by mass spectrometry analysis to identify 
proteins which differentially bind cytosolic cytochrome c in cell types that degrade 
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cytochrome c, versus those cell types where cytochrome c remains intact; 2) take a 
biochemical approach to isolate factors from the cytosol that have the capability of 
ubiquitinating cytochrome c in vitro; 3) ask whether the SCF (Skp1-Cul1-F-box) complex 
plays a role in the degradation of cytochrome c.  SCF is a good candidate for regulating the 
degradation of cytochrome c as SCF recognizes substrates with a WD-40 similar to the WD-
40 repeat by which cytochrome c and Apaf-1 interact (Sun 2003).  
 157
Figures and Legends 
 
 
 
Figure B1: Cytochrome c is degraded upon release from the mitochondria.  Cultures of 
sympathetic neurons were injected with tBid-GFP DNA, and allowed to express for 24 hours.  
Cells were fixed with 4% paraformaldehyde, and cytochrome c and tbid-GFP visualized with 
anti-cytochrome c and anti-GFP antibodies, respectively.  
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Figure B2:  Cytosolic cytochrome c is degraded by the proteasome in sympathetic neurons. 
i) Neurons were maintained in NGF, or deprived of NGF in the presence or absence of 
lactacystin (10 uM) for 24 hrs. Cytochrome c levels were analyzed by Western blot. ii) 
Sympathetic neurons were injected with tBid-GFP in the presence of lactacystin.  After 6 
hours, cytochrome c levels were analyzed by immunofluorescence. 
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Figure B3:  Inhibition of cytochrome c degradation allows apoptosis in sympathetic neurons.   
i) Cultures XIAP-/- sympathetic neurons were injected with tBid-GFP or GFP alone followed 
by treatment with lactacystin (Lact:10 uM) or MG132 (20 uM) with or without zVAD (50 
uM).  Cells were assessed for survival and ii) quantified as percentage of healthy cells at 24 
hrs versus 5 hrs post-injection. 
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C.  APPENDIX C 
Role of the XIAP RING Finger in Cytochrome c-Mediated Apoptosis 
 In neurons, we find that XIAP is a critical inhibitor of cytochrome c-mediated caspase 
activation and apoptosis.  Although the most well documented activity of XIAP is to bind to 
and inhibit caspase activity, whether XIAP uses other means to regulate apoptosis is less 
understood.   
As described in the Introduction, XIAP consists of three BIR domains, as well as a 
RING finger domain.   The BIR3 domain of XIAP can bind directly to cleaved and activated 
caspase-9 (Sun, Cai et al. 2000; Srinivasula, Hegde et al. 2001), while the inhibition of 
caspase-3 and caspase-7 occurs through direct binding to the linker region between the BIR1 
and BIR2 domain (Chai, Shiozaki et al. 2001; Huang, Park et al. 2001; Riedl, Renatus et al. 
2001).  At its C-terminus, XIAP contains a RING finger domain with E3 ubiquitin ligase 
activity (Yang, Fang et al. 2000).  While it is not known whether this domain has a critical 
function within cells, there have been several substrates identified for the RING finger 
domain.  For example, it has been suggested that the RING finger of XIAP can 
autoubiquitinate, and mutants in which the RING domain have been removed become more 
resistant to apoptotic stimuli  (Hay, Wassarman et al. 1995; Yang, Fang et al. 2000).  In 
addition, the RING finger has been described as anti-apoptotic as XIAP has been shown to 
ubiquitinate and target caspase-9, caspase-3 as well as SMAC for degradation (Suzuki, 
Nakabayashi et al. 2001; MacFarlane, Merrison et al. 2002; Morizane, Honda et al. 2005).   
 Sympathetic neurons are one of only two cell types where endogenous XIAP has 
been described as a critical inhibitor of apoptosis.  I therefore used these cell types to ask 
what role, if any, the RING finger domain of XIAP plays in cytochrome c-mediated 
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apoptosis.  To address this, point mutations were made in XIAP to abrogate its caspase 
inhibitory function, but leave the RING domain intact.  The D148A mutation at the linker N-
terminal of BIR2 is unable to bind processed caspase-3, and its ability to inhibit caspase-3 in 
vitro is severely reduced (Silke, Ekert et al. 2001).  The E314S mutation is located in the 
caspase-9 binding groove of the BIR3 domain, and therefore is unable to inhibit caspase-9 
activity (Sun, Cai et al. 2000).  Unlike the wildtype XIAP, expression of the double mutant 
(DM) at low levels in XIAP-/- sympathetic neurons was unable to protect from cytochrome c 
injection (data not shown).  These results indicate that the ability of XIAP to inhibit caspase-
9 and caspase-3 is critical for it to inhibit apoptsis in neurons.  Suprisingly, however, at 
higher expression levels, XIAP-DM protected XIAP-/- sympathetic neurons from 
cytochrome c as efficiently as the wildtype (Fig C1).   
 To address whether the ability of XIAP-DM to inhibit apoptosis is due to a function 
of E3 ubiquitin ligase activity, an H467A mutation in the Ring domain (XIAP-RM) 
abrogating this activity (Yang, Fang et al. 2000) was introduced separately as well as in the 
background of the XIAP-DM, to make the XIAP triple mutant (XIAP-TM).  As expected, 
overexpression of the XIAP-RM, which retains the ability to inhibit caspases, was 
completely able to protect neurons from cytochrome c-induced apoptosis.  However, XIAP-
TM completely lost its ability to inhibit cytochrome c-mediated apoptosis even under the 
overexpression condition, indicating that the RING finger of XIAP is involved in inhibition 
of apoptosis (Fig. C1).   
To ask whether the protection afforded by the RING finger in the XIAP-DM is a result 
of proteasome mediated degradation, XIAP-/- sympathetic neurons expressing XIAP-DM in 
the presence or absence of the proteasome inhibitor, Lactacystin, were injected with 
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cytochrome c.  While XIAP-DM was able to protect neurons from cytochrome c-induced 
apoptosis, Lactacystin treated neurons became completely sensitive to cytochrome c (Fig. 
C2).     
Together, these data suggest that in neurons, the RING finger domain of XIAP may 
have a significant antiapoptotic function.  However, to determine whether the RING finger 
has significant antiapoptotic activity at physiological levels, it would be interesting to ask 
whether there is any difference in the ability of wildtype XIAP and XIAP-RM to inhibit 
cytochrome c-mediated apoptosis when expressed at more physiologic levels.   Indeed, 
expression of wildtype XIAP at 250 pg/ul afforded significantly more protection against 
cytochrome c than equivalent expression of XIAP-RM.  Although the exact targets of XIAP-
mediated degradation are not known, we anticipate that caspase-9 or caspase-3 is a likely 
target, as these have been shown to be ubiquitinated by XIAP in vitro.  
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Figures and Legends 
 
 
 
 
Figure C1: Diagram of XIAP motifs.  Mutations at D148A abrogate the ability of XIAP to 
inhibit caspase-3.  The E314S mutation abrogates the ability of XIAP to inhibit caspase-9.  
Mutation at H467A in the RING domain inhibits XIAP’s E3 ligase activity. 
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Figure C2:  The antiapoptotic activity of XIAP is dependent on its caspase inhibitory 
domains, as well as the RING finger.  (i) XIAP-/- sympathetic neurons were injected with 
plasmids encoding WT XIAP, Vector alone, XIAP-DM, XIAP-TM, or XIAP-RM (200 ng/ul) 
along with EGFP to mark injected cells.  After 24 hours to allow for expression, GFP-
positive neurons were injected with 10 mg/ml cytochrome c.  Cell survival was assessed after 
8 hrs by morphological criteria.  (ii) XIAP-/- neurons were injected with plasmids encoding 
XIAP-DM along with EGFP, and either left untreated, or treated with 10 uM Lactacystin.  
After 24 hrs, to allow for expression GFP-positive neurons were injected with 10 mg/ml 
cytochrome c.  Cell survival was assessed after 8 hrs by morphological criteria.  
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